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ABSTRACT
There is considerable evidence suggesting that frequent, intense, long duration exercise is 
associated with adverse effects on the immune system as shown by a decrease in immune cell 
numbers and functioiL This may ultimately be responsible for the increased rate of infection, 
in particular, upper respiratory tract infection, seen in athletes. It has been suggested that one 
possible mechanism for this immunosuppression is a decrease in plasma glutamine. Glutamine 
is a non-essential amino acid that is utilized at a high rate by immune cells. A decrease in 
plasma glutamine may then impair immune function and possibly lead to increased rates o f 
infection. Recent research has shown that plasma glutamine levels are decreased during times 
o f metabolic and catabolic stress, such as cancer, burns, surgery, endurance exercise and 
overtiaiiung. This decrease in plasma glutamine coupled with the immunocompronused state 
o f these individuals may be evidence o f the important role o f glutamine in immune function 
Recent research has shown that glutamine supplementation results in increased immune cell 
counts and immune function, and decreased rates o f infection in various populations. Therefore, 
the purpose o f this study was to determine the effect o f oral glutamine supplementation on 
resting blood and saliva immune parameters in endurance trained athletes. Fifteen endurance 
athletes (male=9, female = 6, age = 27.9 ± 2.2 yrs, height = 177.0 ±2.1 cm, weight=68.5 ± 
2.8 kg, runiung = 64.1 ± 3.2 km/wk) participated in a randomized double-blind 
glutamine/placebo cross-over stutfy. Thirty grams of glutamine or placebo was provided for 
a duration of 2 weeks, separated by a 4 week washout Resting blood and saliva was collected 
before and after each supplementation period and was analyzed for, total leukocytes, 
neutrophils, monocytes, lymphocytes, T cells, B cells, natural killer, CD4, CD8 cells, saliva IgA 
and plasma glutamine using a 2-way repeated measures factorial ANOVA. The effect of gender 
was analyzed by a 3-way ntixed plot factorial ANOVA. As well, subjects completed a 
nutritional analysis, a life stress questionnaire and a training log during the supplementation 
periods in order to monitor any changes in these control variables. Statistical analysis revealed 
that leukocyte and neutrophil count as well as percent neutrophils for feinale subjects 
significantly increased by 13.7 %, 33.5 %, and 16.1 %, respectively following glutantine 
supplementation, while those receiving placebo decreased by 132 %, 23.2 %, and 10.5 %, 
respectively (p<0.05). There was no significant change (p>0.05) in any immune parameters of 
male athletes. This data suggests that under these conditions oral glutamine supplementation 
may be an effective method of increasing leukocyte and neutrophil counts in endurance trained 
females.
m
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Glutamine and the Immune System 1
Chapter I 
INTRODUCTION
Purpose of the Study
The purpose of this study was to determine the effect of oral glutamine 
supplementation on resting blood and saliva immune parameters in endurance trained 
athletes.
Significance of the Study
During exercise training the duration and the intensity of the program may ultimately 
dictate the effect that the training has on immune function and infection. It has generally 
been accepted that moderate intensity exercise may help improve immune function, which 
will therefore decrease the risk of developing infectioiL On the other hand high intensity 
exercise may be detrimental to immune function and lead to a higher rate of infection in 
athletes (Nieman and Pedersen, 1999). One possible mechanism for the decreased immune 
function and increased infection rates associated with intense exercise and overtraining is a 
decrease in glutamine stores. Recent studies have shown that athletes participating in high 
intensity exercise or those wiio are in a state of overtraining have lower glutamine stores than 
other athletes and control subjects (Parry-Billing et al., 1992; Rowbottom, Keast, Goodman, 
& Morton, 1995; Keast, Arstein, Harper, Fry, & Morton, 1995; Castell et al., 1997).
Glutamine is the most abundant amino acid in the blood and in the muscles. 
Glutamine is the primary fuel for rapidly dividing cells, including leukocytes. In particular.
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glutamine is important for the proliferation of lymphocytes and macrophages. Therefore, 
glutamine is considered to be important in the maintenance of proper inunune function 
(Ardawi & Newsholme, 1985; Hall, Heel, & McCauley, 1996; Walsh, Blanmn, Robson, & 
Gleeson, 1998). Under normal conditions glutamine is considered to be a non-essential 
amino acid. Therefore, glutamine is readily synthesized in the body by other amino acids 
and intermediates (Lacey & Wilmore, 1990). However, during times of catabolic and 
metabolic stress the body’s synthesis o f glutamine does not meet the body’s need for 
glutamine. This imbalance in glutamine homeostasis may then result in glutamine depletion 
and deficiency in these stressed individuals (Walsh et al., 1998).
During times of stress such as when overtrained or during cancer, the body may 
require between 20 to 40 grams of glutamine to maintain proper homeostasis (Krebs, 1935). 
However, most diets provide less than 10 grams of glutamine a day (Hall et al., 1996). 
Therefore, it has been suggested that this glutamine depletion can be corrected by 
supplementing with glutamine in the diet. Furthermore, glutamine supplementation may be a 
useful practice for those individuals experiencing impaired immune function due to various 
physiological stresses (Chandra, 1995).
Several studies involving athletes, individuals with cancer and those with critical 
illnesses have evaluated the role o f glutamine supplementation on immune function, and the 
rate o f infection. Both Castell et al. (1997) and Rohde, Asp, MacLean and Pedersen (1998) 
found that providing glutamine supplementation to athletes following a marathon did not 
show any beneficial results. However, CastelL Poortmans, & Newsholme (1996) found that 
athletes who supplemented with glutamine after running a marathon had a lower rate of
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infection. Similarly, Castell and Newsholme (1997) found that athletes supplementing with 
glutamine after a marathon had a significantly higher CD4/CD8 ratio. Several animal studies 
have been conducted and have shown that glutamine supplementation may increase survival 
rate in rats with bacterial infections and those receiving chemotherapy (Adjei, Matsumoto, 
Oka, Hiroi, & Yamamoto, 1994; Klimberg et al., 1990). It has also been shown that 
glutamine supplementation in tumor bearing rats has a beneficial effect by reducing tumor 
growth (Fahr, Kombluth, Blossom, Schaeffer, & Klimberg, 1994; Klimberg et al., 1992). 
Clinical investigations in humans have shown that glutamine supplementation has beneficial 
effects including, decreased hospital stays, increased immune function, decreased use of 
antibiotics and a decreased overall cost of patient care (Ziegler et al., 1992). Several authors 
have also found that glutamine supplementation increases immune cell proliferation in cancer 
patients receiving radiochemotherapy and in bone marrow transplants (Yoshida et al., 1998; 
Ziegler et al., 1998).
This recent research suggests that glutamine supplementation may be beneficial to 
individuals experiencing catabolic and metabolic stress. Therefore, the intent o f this study is 
to examine the effect of oral glutamine supplementation on resting blood and saliva immune 
parameters in endurance trained athletes.
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Glutamine and the Immune System
Definitions
Ra<;nphik - A type of circulating granulocyte derived from bone marrow with 
structural and functional similarities to mast cells. These cells play an important role in acute 
allergic and inflammatory reactions. They account for 0.5-1 % of the total leukocyte count 
Normal blood concentrations range from 0.01 -0.1 x lO’/L o f blood (Abbas, Lichtman, & 
Pober, 2000; Hofrbrand & Pettit, 1993; Shephard, 1997).
B Ivmnhocvtes - Also known as B cells. The only cell of the immune system capable 
of producing antibodies, therefore making it a central component of the humoral immune 
response. The B lymphocytes mature in the bone marrow, hence the term “B” cell. The B 
lymphocytes account for 5-15 % of the total lymphocytes (Abbas et al., 2000; Hoffbrand & 
Pettit 1993; Shephard, 1997).
CD - Cluster of Differentiation. One or more cell surface molecules, detectable by 
monoclonal antibodies that define a particular cell line or state of cellular differentiation 
(Hoffbrand & Pettit 1993).
Cytotoxic T lymphocytes- Also known as cytolytic T lymphocytes. Sub-class of the 
T-lymphocytes that express the CD8 cell surface antigen. Major function is to recognize and 
kill host cells infected with viruses or other intercellular microbes. The cytotoxic T cells 
comprise 30 - 40 % of the I  lymphocytes population (Abbas et al., 2000; Shephard, 1997).
ECD - Phycoerythrin-Texas Red, excites at 486nm-580nm, and emits at 610nm-
635nm.
ELISA - Enzyme linked immunosorbent assay. Assay used for the detection and 
quantitation of an antibody or antigen using an anti-immunoglobulin conjugated to and 
enzyme which changes color of a substrate (Roitt, 1994).
Eosinophils -These cells are found in the tissues in many diseases, but predominantly 
in two forms: allergy and parasitic infections. They account for 1-6 % of total leukocyte 
count. Normal concentrations range from 0.04 - 0.44 x 10% of blood (Hoffbrand & Pettit, 
1993; Shephard, 1997).
FITC - Fluorescein isothiocyanate, excites at 468nm-509nm, and emits at 504nm-
541nm.
Glutamine - Five carbon amino acid with two amide moieties, an a-amino group and 
a terminal amide group. It is the most abundant amino acid in the blood and in the free 
amino acid pool o f the body. Glutamine plays an important role in the transport o f nitrogen 
between organs. Glutamine is also an important fuel for some cells of the immune system. 
Normal plasma levels o f glutamine range from 500-7(X) ^moI/L (after an overnight fast)
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(Walsh et al. 1998; Hall et al., 1996; Lacey and Wilmore, 1990).
Helper T Ivmphocvtes - A functional sub-class of the T lymphocytes that express the 
CD4 cell surface antigen. These cells main functions are to release cytokines which promote 
the proliferation of T and B cells, activate killer cells, and regulate infiammatory reactions. 
Helper T cells account for 60-70% of the total T lymphocytes (Shephard, 1997).
Immune Response - A complex sequence o f events performed to discriminate 
between host cells and foreign cells and thereby eliminated the latter. It is dependent on 
three main cell types: macrophages, T lymphocytes and the B lymphocytes (Hoffbrand & 
Pettit, 1993).
Immunocompromised - This term will be used interchangeably with 
immunosuppression and immunodeficiency throughout this paper. It is a state o f functional 
unresponsiveness, due in some circumstances to depletion of specific immune components, 
which may have been induced by drugs, physical agents, infection and cancer (Ziegler,
1991).
Immunoglobulin - Soluble factors of the immune defense system. They are 
glycoproteins secreted by B lymphocyte derived plasma cells (Shephard, 1997).
Immunoglobulin A - IgA is the principle immunoglobulin found on the mucosal 
surface and in various secretory fluids (Shephard, 1997).
LAK - Lymphokine-activated killer cells. Have a similar function to natural killer 
cells (Shephard, 1997).
Leukocytes - Also known as white blood cells. All leukocytes express the CD4S cell 
surface antigen. There are groups of cells that mediate the immune response. Normal 
circulating concentrations range from 4-11 x 10% of blood. The leukocytes are further 
differentiated into the neutrophils, eosinopils, lymphocytes and monocytes (Hoffbrand & 
Pettit, 1993; Shephard, 1997).
Lymphocytes - The only cell in the human body capable of recognizing and 
distinguishing different antigenic elements. These cells account for 20-50% of total leukocyte 
count Normal concentrations range from I.5-3.5 x 10% of blood. The lymphocytes are 
further differentiated into the B lymphocytes and the T lymphocytes (Abbas et al., 2000; 
Hoffbrand & Pettit 1993; Shephard, 1997).
Monocvtes - These cells are involved in the central role o f host defense against 
infection. These cells are phagocytotic. These cells are recruited into inflammatory sites, 
where they differentiate into macrophages. They account for 2-10% of total leukocyte count 
Normal plasma concentrations range from 0.2 - 0.8 x 10%  of blood (Abbas et al., 2000;
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Hoffbrand & Pettit, 1993; Shephard, 1997).
Natural Killer Cells - A sub-set of the lymphocytes that function in the innate 
immune response and are important in fighting virus infected tumor cells. These cells 
respond to kill microbe-infected cells by a lysis mechanism and by secreting interferon-Y, 
which activate macrophages to destroy these cells. They account for 10-20 % of total 
lymphocyte count (Abbas et al., 2000; Hoffbrand & Pettit, 1993; Shephard, 1997).
Neutrophils - Also called polymorphonucleur leukocytes (PMN). These cells are 
responsible in maintaining normal host defenses against microorganisms and involved in the 
early stages o f the inflammatory response. These cells are phagocytotic. They account for 
40-75 % of total leukocyte count. Normal plasma concentrations range from 2.5 -7.5 x 
10% of blood (Abbas et al., 2000; Hoffbrand & Pettit, 1993; Shephard, 1997).
Overtraining - A syndrome which usually occurs when the athlete’s training exceeds 
the body’s physiological and psychological capacity to cope with the stress. This often 
results in fatigue, muscle soreness, decreased performance, suppressed immune function and 
increased vulnerability to infection (Kemer & Mellion, 1995; Shephard, 1997).
PC5 - Phycoerythrin-Cy5, excites at 486nm-580nm, and emits at 660nm-680nm.
Phagocytosis - The engulfing of large parasites or other particles by certain cell o f the 
immune system, including neutrophils and macrophages (Abbas et al., 2000).
RDI - Phycoerythrin, excites at 486nm-580nm, and emits at 568nm-590nm.
Suppressor T lymphocytes - A sub-set of the T lymphocytes that secretes cytokines 
that block the activation and function of other effector T lymphocytes (Abbas et al., 2000).
T Lymphocytes - These cells are also known as the T cells. These cells are involved 
in the hosts defense against virus infections. The T lymphocytes mature in the thymus, 
hence the term “T” cell. These cells mediates cell-mediated immune responses in the 
adaptive immune system. The T lymphocytes account for 60-75% of the total lymphocytes. 
The T lymphocytes are further differentiated into the T helper and T cytotoxic cells (Abbas 
et al., 2000; Hoffbrand & Pettit, 1993; Mackiimon, 1999; Shephard, 1997).
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Chapter 2 
REVIEW OF LITERATURE
The immune system is a unique and complex system of the body that has developed 
the ability to distinguish the body’s own cells from foreign cells. The ability to perform this 
function allows the immune system to protect the body against foreign elements such as 
microorganisms, viruses, allergens, tumour growth and cell and tissue transplantation 
(Mackinnon, 1999).
The immune system can be simplified into two main components; innate immunity 
and adapuve immunity (Table I ). Innate immunity or natural immunity is the component of 
the system that occurs immediately. Although the innate defence is immediate, it has 
predetermined nonspecific protection against an immune challenge. However, this is the 
body’s first line of host defence. Innate immunity includes physical barriers, chemical 
barriers, and cellular components (Mackinnon, 1999; Shephard, 1997). Adaptive immunity 
or acquired immunity occurs due to a response to a pathogetL The adaptive component of 
the immune system is specific to a given foreign nucromolecule. The major components of 
adaptive immunity include, humoral factors and cellular factors. Both the innate and 
adaptive systems work together in order to provide optimal host defence (Mackinnon, 1999; 
Shephard, 1997).
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Components of Innate and Adaptive Immunity





















Granulocytes (e.g., neutrophils) 
Natural Killer Cells
Table I.
Cells of the Immune System
Leukocytes or white blood cells (WBC) are found in various tissues in the body, as 
well as in the blood and lymph circulation. Leukocytes originate from stem cells in the bone 
marrow, but certain cell types mature in the thymus (T lymphocytes) and bone marrow 
(B lymphocytes). Leukocytes migrate between different lymphoid tissue via the circulation 
and lymphatic system. Only 1-2 % of the body’s total leukocytes are present in the blood at 
any given time (Mackinnon, 1999).
The number of leukocytes in normal blood ranges between 4-11 x 10% of blood.
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Fluctuations occur during the day, with the lowest values occurring during rest These 
leukocytes are further broken down Into sub-populations with specific functions during the 
immune response. The major types of leukocytes found in the circulation are the 
granulocytes, monocytes, and lymphocytes. The granulocytes sub-set o f the leukocytes 
includes the basophils, eosinophils, and neutrophils. The basophils are the least common of 
all the circulating granulocytes. They account for 0.5 -1%  (0.01-0.1 x 10% of blood) of the 
total blood leukocytes in the body. These cells release histamine and other substances which 
play an important role in acute allergic and inflammatory reactions. The eosinophils account 
for approximately 1 - 6 %  (0.04 - 0.44 x 10% of blood) of the total blood leukocyte count 
in the body. These cells are involved in phagocytosis and are active against parasites that are 
too large to be engulfed by the other types of leukocytes. The eosinophil can also generate 
reactive oxygen species that attack the cell membranes of invading organisms. The 
neutrophils make up the largest portion o f the leukocytes comprising approximately 40-75 
% (2.5 - 7.5 X 10% of blood) of the total blood leukocyte concentration. Neutrophils are 
phagocytic, and can engulf and digest bacteria, microorganisms and microscopic particles. 
They have the ability to enter tissues early in the inflammatory response and are also able to 
mediate antibody-dependent cell-mediated cytotoxicity (ADCC). The monocytes form 2 - 
10 % (0.2 -0.8 X 10% of blood) of the total leukocyte concentration. The majority of the 
monocytes leave the blood and develop into macrophages in various tissues. These cells are 
involved in phagocytosis and secrete cytokines which activate other elements o f the immune 
system (Mackiimon, 1999; Roitt, 1994; Shephard, 1997).
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The lymphocytes account for 20 - 50 % ( 1.5 - 3.5 x 10% of blood) o f the total 
blood leukocyte concentration. The lymphocytes are further broken down into the T 
lymphocytes or T cells, B lymphocytes or B cells and the natural killer cells. The T- 
lymphocytes account for approximately 60 - 75 % of the total lymphocyte count and are 
involved in the defense against virus infections. All T lymphocytes carry the CD3 cell 
surface antigeru The T lymphocytes are differentiated further into two major groups, the T 
helper and T cytotoxic cells. The T helper cells account for 60-70% of the total T 
lymphocytes and carry the CD4 cell surface antigen. The main function o f these cells are to 
release cytokines which promote the proliferation of T and B cell, activate killer cells, and 
regulate inflammatory reactions. The T cytotoxic cells carry the CD8 cell surface antigen and 
account for 30 - 40 % of the total T lymphocyte population. These cells are activated by 
cytokines, and directly destroy infected cells by recognizing the foreign surface constituents 
o f these abnormal cells. Natural killer cells represent 10 - 20 % of the total circulating 
lymphocyte population and are characterized as being large granular lymphocytes. Natural 
killer cells are defined as a subset of the lymphocytes as cells expressing the CD16 and 
CD56 surface antigens but they lack the CD3 surface antigetL These cells function to 
recognize and kill tumor and other viral infected cells (Mackirmon, 1997; Shephard, 1997).
The B lymphocytes account for 5 -15 % of the total lymphocytes and carry the 
GDI9 cell surface antigen. B lymphocytes are stimulated by T helper cells in response to an 
infection. These B cells then differentiate into plasma cells that produce and secrete 
antibodies. An antibody is an immunoglobulin (Ig) that reacts specifically with an antigen.
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There are five classes of immunoglobulins (IgG, IgA, IgM, IgD, IgE), each with distinct 
properties. Immunoglobulin A (IgA) is the predominant Ig in mucosal secretions found in 
tears, breast milk, and fluids of the respiratory, genitourinary, and gastrointestinal tracts.
Exercise and Immunology
Throughout the fimess/sports world the general belief is that regular physical activity 
is beneficial and will help decrease an individual’s risk of infection. However, recent 
literature has suggested that the duration and intensity of the exercise is very important when 
determining the effect of various exercise and training programs on the active individual 
(Nieman & Pedersen, 1999). Research has suggested that moderate intensity exercise may 
help increase immune function and therefore may reduce the risk of acquiring various 
infections. A number of studies have looked at this phenomenon and found that low to 
moderate intensity exercise is beneficial to immune function. Newsholme ( 1994) indicated 
that low intensity exercise enhances lymphocyte response and natural killer cell activity in the 
circulating blood. Nieman et al. (1993) found that the incidence o f upper respiratory tract 
infection was less in active subjects compared to sedentary subjects. The results showed that 
the individuals participating in a walking program had a 21 % (p< 0.042) incidence of 
infection compared to a SO % incidence o f infection in the matched-pair control subjects. 
Furthermore, Nieman, Nehlsen-Gannarella, et al. (1990) found that individuals participating 
in a walking program reported fewer days of infection (5.1 days, p< 0.039) compared to the 
inactive control subjects (10.8 days).
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Although low to moderate intensity exercise may be beneficial to immune function 
and possibly help decrease the risk of infection in these individuals, high intensity exercise 
has been shown to elicit the opposite effect Several clinical and epidemiological studies 
have indicated that athletes are at a higher risk of infection after intense training or following 
competitive events (Nieman and Petersen, 1999). It has been suggested that prolonged 
cardiovascular endurance exercise may lead to a significant change in immune function 
therefore increasing the risk of infection in these athletes. After this type of exercise there 
may be an “open window” which may allow viruses and bacteria to gain a  foothold, which 
may in turn increase these athletes’ risk of infection following exercise (Nieman and 
Petersen, 1999). Newsholme (1994) also states that these changes in the immune system 
associated high intensity long duration exercise may have a adverse effect on the health of 
the athlete, in particular during times of increased training. This may result in the athlete 
being more susceptible to infection during crucial times in the season. There is considerable 
evidence that shows that athletes participating in high intensity exercise have decreased 
immune function and a higher incidence of infection compared to the general population. 
Newsholme ( 1994) reports that this type of athlete has been shown to have a higher 
incidence of upper respiratory tract infection (URTI) and intestinal problems than the 
general population. Nieman, Johanssen, Lee, Cermak, & Arabatzis (1990) reported that 
12.9 % of individuals participating in the 1987 Los Angeles marathon experienced upper 
respiratory tract infections while only 2.2 % of the nonrparticipating control subjects (who 
did not participate) experienced upper respiratory tract infections. It was also discovered 
that runners who had trained at a volume of 96 km/week (for a period o f 2 months fnior)
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doubled their odds o f getting an infection compared to those athletes who trained at a 
volume of 32 km/week. Peters and Bateman (1983) also found an increased infection rate in 
athletes participating in intense competition. The results from this investigation indicated that 
the incidence o f upper respiratory tract infection was 33.3 % in runners after a 56 km 
marathon compared to only 15.3 % in the control subjects not participating in the marathon. 
These results, were in line with the finding of Peters (1990) who found a 28.7 % infection 
rate in marathon runners competing in a 56 km marathon as compared to a 12.9 % rate o f 
infection in the control subjects not participating in the marathort It has also been suggested 
that rurming mileage is a significant risk factor for developing URTI (Heath et al., 1991).
The relationship between upper respiratory tract infection and exercise has been 
explained by Nieman (1994) as being a J-shaped curve as depicted in Figure I. This 
relationship proposes that sedentary individuals will have an average risk of developing an 
upper respiratory tract infection while subjects who are involved in moderate intensity and 
duration exercise will have a below average risk of developing an URTI. Furthermore, as 
training intensity and duration increases so will the risk of developing an URTI. Therefore, 
manipulating training intensity and duration will either increase or decrease an individual’s 
chance of developing an URTI.
These increased infection rates may ultimately be due to a decrease in immune 
function in these individuals. There is considerable evidence that prolonged exhaustive type 
exercise has a detrimental effect on immune cells, in particular the natural killer cells, 
neutrophils, lymphocytes, T-lymphocytes, B-lymphocytes, CD4/CD8 ratio and
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Amount and Intenshy of Exercise
Figure I c u r v e  model oa the relitioashvbetwea amount and rniensiQr of 
exerdse and risk o f u|>paTespinloiy tract nÀetion (URTI) (Nieman, 1994).
immunoglobulins (Gleeson et al., 1995; Lehmann et al., 1992; Lehmann et al., 1996; 
Mackinnon & Hopper, 1996; Nieman and Pedersen, 1999; Newsholme, 1994; Northoff, 
Enkel, & Weinstock, 1995; Pyne et al., 1995). Mackinnon, Ginn, & Seymour (1993) 
showed that elite squash and hockey players had a lower salivary immunoglobulin A (s-lgA) 
preceding an upper respiratory tract infection. McDowell et al. (1992) also found that 
salivary immunoglobulin A was decreased by 24.4 % (p< 0.05) after subjects completed a 
maximum treadmill test
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Frisina, Gaudiere, Cable, Keast, & Palmer ( 1994) found that the percentage of 
T lymphocytes and B lymphocytes decreased by 14 % (p <0.01) and 9 % (p< 0.01), 
respectively after subjects exercised at 112 % of their maximum aerobic work capacity.
There was also a decrease of 47 % (p< 0.05) in the CD4/CD8 ratio associated with this 
exercise protocol. The authors state that a reduction in the CD4/CD8 ratio that occurred 
after exercise may have detrimental effects on the athlete.
Collectively, these data suggest that following prolonged exercise, immune function is 
suppressed and therefore it would make sense that athletes participating in these types of 
events or training regimens would have a higher incidence of infection than athletes 
participating in moderate intensity exercise (Nieman and Pedersen, 1999).
Glutamine
Proteins are important parts of our diet because they help support growth and repair 
various components in the body. These proteins are made up of smaller units called amino 
acids. Amino acids are commonly found in food and can also be synthesized in the body 
from other amino acids. The amino acids that carmot be synthesized in the body are termed 
"'essential'' amino acids. Therefore, these amino acids must be supplied from an exogenous 
source (our diet). The remaining amino acids can be synthesized in the body ftom other 
amino acid and intermediates. Thus, these amino acids are termed “non-essential” or 
“dispensable” amino acids. Therefore, under normal physiological conditions there is no 
real need for these non-essential amino acids in our diet (Lacey & Wilmore, 1990).
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However, under certain physiological conditions the need for some of these non- 
essential amino acids may be greater than the endogenous (body’s) rate of synthesis. 
Therefore, an amino acid that is usually considered to be non-essential becomes essential for 
this individual at that particular point in time. When this occurs, this amino acid is 
considered to be “conditionally” essential, therefore becoming necessary under that particular 
physiological condition (Lacey & Wilmore, 1990).
One example of a conditionally essential amino acid in human nutrition, is cysteine 
for newborns. This amino acid is essential because newborns are not mature enough to 
produce the enzyme (cystathionase) needed to synthesize cysteine in the body. Another 
example would be tyrosine and cysteine in individuals with liver problems. Due to the fact 
that these individuals livers have lost the ability to synthesis these non-essential amino acids, 
an exogenous source of tyrosine and cysteine is essential (Gaull, Rassin, Raiha, & Heinonen, 
1977; Lacey & Wilmore, 1990). Recently, glutamine has been identified as possibly being a 
conditionally essential amino acid for individuals experiencing catabolic and metabolic stress 
(Lacey and Wilmore, 1990).
Glutamine is the most abundant amino acid in the blood and in human muscle 
(Calder, 1995; Lacey and Wilmore, 1990). The concentration of glutamine in the skeletal 
muscle contributes approximately 60 % of the total ftw  amino acid pool (Calder, 1995). 
Normal plasma glutamine concentrations range from 500-700/imol/I (Castell 6  Newsholme, 
1997). Glutamine is the most important nitrogen carrier and it is essential for protein 
synthesis and cell proliferation in the botfy (Rohde, MacLean, & Pedersen, 1998).
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Skeletal muscle has the enzymatic capacity to synthesize glutamine. Therefore, 
skeletal muscle is the major tissue involved in glutamine production and is the major tissue 
that releases glutamine into the blood. It has been suggested that the skeletal muscle plays a 
vital role in the process that regulates glutamine utilization by the immune system in the 
blood. Therefore, any activity that involves the skeletal muscle may ultimately affect the 
immune system. Although the skeletal muscle can synthesize glutamine under normal 
conditions, it has been suggested that during times o f metabolic stress, such as cancer, 
bums, sepsis, surgery and after exhaustive type exercise, the body’s synthesis may not meet 
the body’s requirements. This mayiesult in a glutamine deficiency in these individuals and 
impair their immune function (Ardawi & Newsholme, 1985; Rohde, Asp et al., 1998).
Animal studies have shown that the concentration of glutamine in skeletal muscle is 
lower in stress situations, such as sepsis, cancer and after bum injuries (Calder, 1995).
These findings are similar in humans where decreased plasma concentrations are also 
lowered by sepsis, injury, bums, surgery, endurance exercise and overtraining.
Furthermore, research has shown that intramuscular glutamine stores are lowered by 50 % in 
these situations (Calder, 1995; Parry-Billing, Evans, Calder, & Newsholme, 1990).
The observations that lower plasma glutamine concentrations occur during these 
situations has led some to suggest that this is due to the increased demand by other tissues 
such as the kidney, liver, gut and the immune cells ((Zalder, 1995).
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Glutamine and the Immune System
Glutamine is known to be an important fuel for some cells of the immune system, in 
particular lymphocytes and monocytes (Newsholme, 1994; Nieman and Petersen, 1999). 
Data has also suggested that the CD4 cells (T helper) have an above average dependence on 
glutamine when stimulated in vitro (Hack et al., 1997; Tvede et al., 1989). The high rate of 
glutamine utilization even at rest permits these cells to respond to an immune challenge 
without delay. For example, B and T lymphocyte proliferation occurs when a foreign 
microorganism is invading the body. When this occurs, these cells must respond as rapid as 
possible in order to defend the host Any delay in the response to this microorganisntcaused 
by a low rate of fuel (glutamine) may result in a late response and may result in an 
ineffective control of the foreign agent (Newsholme, 1994).
Several iirununostimulator actions of glutamine have been reported, including in vitro 
proliferation o f lymphocytes in rats, mice and humans. Furthermore, when glutamine is 
absent these lymphocytes do not proliferate, but as glutamine concentrations in culture 
increase, lymphocyte proliferation also increases (Ardawi & Newsholme, 1983; Calder,
1994; Parry-Billing, Blomstrand, McAndrew, & Newsholme, 1990).
Due to the fact that some cells of the immime system are dependent on glutamine 
concentrations in vitro at a specific physiological range, immune cells in vivo may also be 
dependent on glutamine over this same range. Therefore, it would be likely that decreased 
plasma glutamine concentrations would at least partially lead to immunosuppression in the 
human host (Calder, 1994). Due to the importance o f glutamine to the cells o f the immune
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system, there has recently been some evidence to support the hypothesis that decreases in 
immune function may be in part due to a decrease in plasma glutamine levels (Hack et al., 
1997).
Glutamine and Exercise
After exhaustive type exercise glutamine concentrations have been shown to decrease 
below pretesting values. Newsholme, Parry-Billing, McAndrews, & Bidgett (1991) showed 
that plasma glutamine concentration decreased by 16 % after a marathon race and still 
remained decreased for several hours after the race. Athletes who were diagnosed as being 
overtrained also showed a significantly lower (9%) glutamine concentration compared to 
match paired control subjects (Parry-Billing et al., 1992). Rowbottom et al. (1995) found 
similar results when comparing 10 athletes diagnosed to be overtrained to match-paired 
controls not diagnosed as being overtrained. The plasma glutamine concentrations of the 
overtrained athletes were significantly lower (704 ^mol/L, p< 0.01) compared to the control 
subjects ( 1000 /zmol/L). Keast et al. ( 1995) foimd that when subjects ran at 90 % and 120 
% o f their VO^max there was a 44 % (p< 0.05) and a 55 % (p < 0.01) decrease in plasma 
glutamine level compared to pretest values. Furthermore, Castell et al. (1997) found that 
after subjects participated in a marathon plasma concentrations decreased by 19 % (p< 0.05) 
coupled with a 40 % (p< 0.01) decrease in natural killer cell concentrations.
It is unclear what the underling mechanism is for the decreased glutamine 
concentration seen following long term exercise and overtraining. However, it is possible 
that these conditions interfere with the control o f the rate o f glutamine released from the
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muscle and therefore cause a decreased glutamine concentration in these individuals 
(Newsholme, 1994). Parry-Billing et al. (1992) have also suggested that overtraining may 
decrease the rate o f glutamine released by the muscle, therefore causing a decrease in plasma 
glutamine concentration and adversely affecting immune cell concentrations. Therefore, it 
has been suggested that the immunosuppression and increased infection rate associated with 
high intensity, long duration exercise and overtraining may be in part, a result o f low plasma 
glutamine concentrations (Keast et al., 1995; Parry-Billing et al., 1992).
Rowbottom et al. (1995) have modified the J curve presented by Nieman (1994) by 
adding plasma glutamine concentrations to the model to explain the relationship between 
upper respiratory tract infection and glutamine concentration, as seen in Figure 2. It is 
proposed that sedentary individuals will have both an average glutamine concentration and 
an average risk of developing an upper respiratory tract infection, whereas individuals 
engaged in moderate amounts and intensity exercise will have a higher glutamine 
concentration and a lower risk of developing a URTl. Furthermore, as amount and intensity 
of exercise increases there will be a decrease in glutamine concentrations coupled with a 
higher risk of developing an URTI.
Because lower glutamine concentrations have been associated with decreased 
immune function and increased infection in intense training athletes, it has been suggested 
that plasma glutamine concentrations can be a helpful tool in determining overtraining 
status. Although some evidence indicates that symptoms occurring during
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Figure 2 • Modified “J” curve o f the relmdomehip between various o f  exercise and both
upper lespiratoiy oact infixtioo (URU) and plasma glutamme cooeemtations gtowbouom et sL . 
1995).
falls in glutamine levels are parallel to those seen during overtraining syndrome, further 
research should be conducted to determine its validity as a physiological marker for 
overtraining (McKenzie, 1999; Rowbottom et al., 1995). However it has recently been 
suggested that glutamine concentrations are a useful tool in monitoring tolerance to training 
volume (Smith & Norris, 2000).
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Glutamine Supplementation
Moderately severe protein energy malnutrition has been shown to impair a number of 
immune responses including decreased I  lymphocyte levels and in particular the CD4 
concentration. Therefore, a modest increase in the amounts of some nutrients such as 
glutamine may enhance immune function. This may be a useful practice in the management 
of individuals experiencing impaired immune function due to a particular physiological stress 
such as surgery, cancer, and overtraining (Chandra, 1995).
Due to the fact that plasma glutamine concentrations decline during catabolic illness 
in spite of the increased release from the muscle. Smith and Wilmore (1990) suggest that 
endogenous synthesis is not adequate to meet the increased demands of glutamine utilization 
and therefore, a deficiency may develop. During these times of physiological stress it may 
be important to consume 20 - 40 grams of glutamine per day to maintain proper homeostasis 
in the body (Krebs, 1935).
Most naturally occurring proteins contain 4 • 8 % of their amino acid composition as 
glutamine. However, the daily consumption o f glutamine has been estimated to be less than 
10 grams per day (Hall et al., 1996). If we examine the above value ( 4 - 8  %) and the 
Recommended Dietary Allowance (RDA) for protein (0.8 grams/kg of body weight), a 75 
kg individual meeting their RDA would consume approximately 2.5 - 5 grams of glutamine 
a day. This value is consistent with that o f Hall et al. (1996).
The high rate of glutamme utilization by the lymphocytes, macrophages and other 
immune cells coupled with the increased dietary need for glutamine during times o f 
physiological stress, suggest that the provision o f glutamine may be important in the
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maintenance of immune function. Data has suggested that an optimal amount o f glutamine 
is required for the immune system to function effectively (Calder, 1995). Therefore because 
of glutamine’s stimulatory effect on immune function, it would seem appropriate to provide 
glutamine to individuals after surgery, bums, sepsis, injury and exhaustive training or 
exercise (Calder, 1995).
Safety of Glutamine Supplementation
Several studies have looked at the safety o f glutamine supplementation in humans. 
Ziegler et al. ( 1990) found that glutamine at a dose of 0.57 grams«kg ' body weight per day 
is well tolerated in healthy humans in the form of an oral or intravenous bolus, as short-term 
infusion or as a major part of intravenous formulas. The authors also state that glutamine 
supplementation appears to be safe in bone marrow transplant patients for a period of up to 
four weeks. Furthermore, glutamine was readily metabolized and cleared from the blood 
without significant generation of toxic end products. Lacey et al. ( 1996) also found that 
premature infants fed 20% of their total protein requirements as glutamine had no abnormal 
biochemical effects. Savy (1997) notes that common hospital feeding of glutamine to adults 
is prescribed at a dose of 30 grams daily divided into three 10 gram doses. This dose can be 
adjusted to 20 grams for smaller individuals and 40 grams for larger individuals.
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Cancer and Critical Illness Studies
Several animal studies have evaluated the effect o f glutamine supplementation on 
immune function, tumor size and mortality. Adjei et al. ( 1994) fed mice a standard casein 
diet or a diet supplemented with 4% (by weight) glutamine. The mice were then inoculated 
with Staphylococcus aureus (bacterial infection) and monitored for a period o f 20 days.
The results indicated that there was only a 20 % survival rate in the mice fed casein and a 66 
% survival rate in the mice fed glutamine. Klimberg et al. (1990) found similar results in rats 
receiving whole abdominal radiation. Rats who received 3 % glutamine as part o f their diet 
had a 100% survival rate whereas those rats fed 3% glycine as part of their diet had only a 
45% (p< 0.01) survival rate.
In a study with tumor bearing rats, Fahr et al. (1994) fed half o f the rats a glycine 
diet while the remaining rats received glutamine. The results showed that the rats fed a 
glutamine diet had a 40 % decrease in tumor growth coupled with a 30 % increase in natural 
killer cell activity. The authors suggest that glutamine supplementation may help reduce 
tumor size by promoting natural killer cell activity. Similarly, Klimberg et al. (1992) found 
that when rats receiving chemotherapy (methotrexate) were fed glutamine as part of their 
diet, they had nearly double the loss in tumor volume compared to those receiving glycine as 
part o f their diet
Clinical investigations indicate that glutamine supplementation in critically ill patients 
resulted in a decreased rate of infection, a decreased use o f antibiotics, an increase in 
immune function, a decreased hospital stay and an overall decrease in the cost o f care 
(Wilmore et al. 1999). Clinical investigations with cancer patients have also found positive
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results following glutamine supplementation. Yoshida et al. (1998) examined the effect of 
glutamine supplementation in patients with advanced esophageal cancer receiving 
radiochemotherapy. Results indicated that glutamine supplementation in these patients 
prevented a reduction in the lymphocyte count (1007 ± 151 vs 567 ± 96 cell/mm^, p< 0.01), 
T lymphocyte count (854 ± 106 vs 467 ± 80 cell/mm^, p <0.05), and B lymphocyte count 
(86 ± 13 vs 45 i  14 cell/mm\ p <0.05) compared to those not receiving glutamine after 7 
days. The authors suggest the oral glutamine supplementation protects lymphocytes in 
patients with advanced esophageal cancer receiving radiochemotherapy.
Ziegler et al. (1992) found that bone marrow transplant patients who supplemented 
with glutamine developed less infection (3 vs 9, p = 0.041), had shorter hospital stays (29 ±
1 days vs 36 ±2 days, p = 0.017), and that hospital charges were S21 095 less per patient 
compared to individuals receiving placebo. Ziegler et al. (1998) found that bone marrow 
transplant patients supplemented with glutamine as part o f their parenteral nutrition had 
improved immune plasma profiles compared to those receiving standard parenteral nutrition 
formulas. The glutamine supplemented patients had an increased lymphocyte count (590 ± 
71 vs 332 ± 50 ccHs/mL, p = 0.01), greater T lymphocyte count (229 ± 70 vs 54 ± 19 
cells//.iL, p = 0.03), greater CD4 (44 ± 10 vs 19 ± 6 cells/AtL, p = 0.048), and increased CD8 
count (101 ± 15 vs 53 ± 10 cells//iL, p= 0.015). The authors suggest that glutamine 
supplementation may support lymphocyte recovery after bone marrow transplants.
Schloerb and Amare (1993) found that bone marrow transplant patients who 
supplemented with glutamine had a significantly shorter hospital stay (26.9 ± 1.3 days) 
compared to those standard parenteral nutrition formulas (32.7 ± 2.1, p 0 .05). The authors
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Glutamme and the Immune System 26
suggest that this decrease in hospital stay had significant implications towards overall patient 
care and hospital economics. Care for these patients was conservatively estimated at $1000 
per patient per day. The authors further suggest that if the hospital had 30 patients a year, 
these results would lead to SI 80 000 savings a year. Furthermore, a saving of approximately 
1 week (5.8 days) in hospital stay would make available 270 extra bed days per year. This is 
all at the cost of less than S3 a day for 40 grams of glutamine. Jensen, Miller, Talabiska, 
Fish, & Gianferante (1996) studied intensive care unit patients and found improvements in 
immune function with glutamine supplementation. Patients who supplemented with 
glutamine enriched nutritional formulas showed a higher CD4/CD8 ratio compared to 
baseline values of those who were supplement with a standard nutritional formula. These 
results seem very promising, however, additional, research is needed to determine the effect 
of glutamine supplementation on the immune function of individuals with cancer. 
Furthermore, the effect of oral glutamine supplementation should be evaluated to determine 
its effectiveness as a nutritional therapy.
Training Studies
Few studies have evaluated the effect o f glutamine supplementation on athletes and 
the few that have been conducted have shown mixed results. Castell et al. (1997) found that 
glutamine supplementation provided to male athletes after a marathon had no effect on 
lymphocyte distributioiL Rohde, Asp, et al. (1998) also found that there was no benefit 
when male athletes were provided glutamine. Subjects in that study were provided with 
glutamine or placebo after a marathon to determine the effect on leukocyte subsets. Results
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indicated that glutamine supplementation did not have any effect on any leukocyte subsets in 
subjects after a marathon. In a similar study Rohde, MacLean, et al. (1998) had male 
subjects perform three bouts of cycle ergometry lasting 60,45, and 30 minutes at 75 % 
VOjmax separated by two hours rest. Although glutamine concentrations were higher in the 
glutamine supplemented group there was no difference in circulating lymphocytes between 
groups. Furthermore, Walsh, Blannin, Bishop, Robson, & Gleeson (2000) had male 
subjects cycle for 2 hours at 60 % VOjmax, while receiving a sugar free drink every 15 
minutes for the first 90 minutes of exercise followed by a glutamine or placebo drink for the 
remainder of the exercise protocol and for 2 hours of recovery. Analysis revealed that 
glutamine supplementation had no effect on the magnitude o f post-exercise leukocytosis, and 
neutrophil function as assessed by oxidative burst activity.
Some authors have found that glutamine supplementation results in positive effects 
on ittunune function following exercise. Castell, Poortmans, & Newsholme (1996) had male 
and female subjects supplement with either glutamine or a placebo after a marathon or ultra­
marathon. Subjects were then required to report their incidence of infection for a period of 
seven days. The results indicated that subjects reporting no infections were significantly 
higher in the athletes receiving glutamine (80.8 ± 4.2 %, p< 0.001) compared to the athletes 
receiving placebo (48.8 ± 7.4 %). It has also been reported that a mixed group of male and 
female athletes receiving glutamine following a marathon or ultra-marathon had a 
significantly higher CD4/CD8 ratio then athletes receiving a placebo (Castell & Newsholme, 
1997).
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To this author’s knowledge, all studies to date involving athletes and glutamine 
supplementation have looked at the effect of glutamine following a one day (acute) exercise 
session. In these studies blood sampling is often performed during or immediately following 
exercise. This may be a problem because leukocyte count may be increased from the normal 
values o f4500-11000 cells per mm^ to an excess o f20000 cells per mm^ following physical 
exertion (UR, 1999). Therefore, a major increase in leukocyte count after exercise may 
mask any effect (either positive or negative) that may occur by providing glutamine 
supplementation. If blood sampling was performed at times when leukocyte count was near 
normal daily baseline values, the effect o f  glulamine supplementation could be better 
evaluated. Also, no study to date has evaluated the effect of long term (more than 1 day) 
glutamine supplementation on the immime function of athletes. The supplementation 
period, as well as the time of blood sampling may be important points to consider when 
trying to determine the effect of glutamine supplementation on the immune system of 
athletes. These points will be addressed during this study. Also, by using a longer 
supplementation period, a larger dose and evaluating the effect of the supplementation 
during chronic training the author feels that this may be more applicable to most athletes.
In summary, there is considerable evidence that during times of metabolic and 
catabolic stress, glutamine concentrations in the body become depleted. Due to the 6 c t that 
many immune cells are dependent on glutamine as their primary fiiel source, immune 
function may become impaired under these conditions. During these particular conditions 
glutamine may then be considered to be a conditiotially essential amino acid because the
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body’s synthesis cannot meet it’s own needs. Therefore, supplementation with glutamine 
may be an effective way of improving glutamine status, facilitating immune function, 
decreasing infection, and improving the overall health o f athletes after intense prolonged 
exercise or those experiencing overtraining syndrome.
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All subjects for this study participated on a volunteer basis and were free to withdraw 
from the study at any time. Prior to commencement of the study, all subjects were informed 
about the purpose of the study before giving written consent to participate. All ethical 
guidelines established by Lakehead University Ethics Advisory Committee were followed.
Fifteen males and females (male = 9, female = 6, age = 27.9 ± 2.2 yrs, height =
177.0 ± 2.1 cm, weight = 68.5 ± 2.8 kg, running = 64.1 ± 3.2 km/wk) endurance athletes 
from the Thunder Bay District currently active in aerobic training were selected to participate 
in the study. Selection criteria was determined by using a questionnaire which allowed the 
researchers to determine the subjects health status, training volume, training intensity, and 
dietary practices (supplements taken). To participate in the study subjects meet the following 
criteria:
Selection Criteria
1) Having no known physical or mental conditions that may effect their participation in the 
study.
2) Training at a volume of at least 50 km per week.
3) The expectation and willingness to maintain their regular training routine for the duration 
of the study (8 weeks).
4) The expectation and willingness to maintain their regular dietary intake throughout the 
duration of the study, wdiile including the appropriate supplement (placebo or glutamine) as 
part of their regular diet
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5) The willingness to provide a 3 day dietary intake summary before and after each 
supplementation period.
6) Not currently taking any other supplement (eg. creatine, protein drinks etc.) throughout 
the entire study.
7)The expectation and willingness to maintain a regular training log, outlining training 
volume frequency and intensity during each o f the 2 week supplementation periods.
8) Willingness to provide a blood and saliva sample during four separate occasions 
throughout the study.
Exclusion Criteria after Selection
Subjects selected to take part in the study were excluded from analysis if  any of the 
following conditions occurred;
1 ) Not providing a blood and saliva sample at each of the four sample collection periods.
2) Not ingesting at least 90 % of the supplement during each of the 14 day supplementation 
periods. Instructions will be given to subjects to return all unused supplement and 
calculations will be made.
3) Not maintaining their training at a level o f ± 20% o f their regular training volume.
4) Not providing a 3 day dietary intake summary before and after each supplementation 
period.
Experimental Design
The study was a randomized double-blind glutamine/placebo cross-over design study 
which took place over a period of 8 weeks. Subjects acted as their own control as they 
supplemented with both placebo and glutamine for 2 weeks (14 days) with a 4 week washout 
period between supplementation periods. There is a lack of research examining the time 
needed for an adequate washout when supplementing with glutamine. Walsh et al. (2(XX))
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and Rhode, MacLean et al. (1998) had subject supplement with glutamine for a single day 
and utilized a 7 day washout Although the supplementation period in this study is longer 
than these previous studies the authors feel that this will be adequate. Furthermore, the 
effectiveness o f the washout will be tested prior to further analysis. Seven of the subjects (S 
males, 2 females) were randomly assigned to supplement their diet with glutamine for 2 
weeks and after a 4 week washout period they then supplemented with placebo for an 
additional 2 weeks (GT/PL). The remaining eight subjects (4 males, 4 females) 
supplemented their diet with placebo for 2 weeks and then after a 4 week washout period 
they then supplemented with glutamine for an additional 2 weeks (PL/GT). Eadrsubject 
was required to visit the laboratory on four separate testing sessions (Tl, T2, T3, and T4). 
Test one (Tl ) was performed on day 1, whereas test two (T2) was performed on day 15.
Test one (Tl ) and test two (T2) were separated by supplementation period one (SI ) which 
started on day 1 and ended on day 14. This is the supplementation period before the four 
week washout period (W). Test three (T3) was performed on day 44 of the study (after the 
washout period) whereas test four (T4) was performed on day 58 of the study (after 
washout period). Test 3 (T3) and test 4 (T4) was separated by supplementation period two 
(52), which started on day 44 and ended on day 57 of the study (Figure 3).
(T l)___ ^ (SI) ___ ^ (T2)
D n r lH H i► Day 1-14 ► Day 15"
Test 1 - Test2-
Blood Period 1 -Half Blood
and Saliva Ifae subjects and Saliva
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Haematological and Saliva Collection
Subjects reported to the laboratory in the morning (between 7-9 am) before and 
after each supplementation period (Tl, T2, T3, T4) in a fasted state. Subjects were also 
instructed to avoid physical activity for a period of 12 hours. Subjects provide both a blood 
and saliva sample during each of their visits to the laboratory. All blood sampling was 
performed by a certified Phlebotomist after subjects had rested (seated) in the laboratory for 
a period of 30 minutes. Blood was collected in Vacutainer^ tubes by using an antecubital 
venipuncture technique. Two blood samples were collected ftom each subject on each visit 
to the laboratory. A 2.5 ml blood sample was collected in a Vacutainer^ tube containing the 
anticoagulant ethlyenediaminetetraacetic acid (EDTA). This sample was used for all 
haematological analysis (Complete Blood Count and Lymphocyte Differentials). A second 8 
ml blood sample was collected in a Sodium Heparin Vacutainei^ tube. This sample was 
immediately placed on ice until centrifugation. This sample was centrifuged at 3000g for 10 
minutes and then plasma was extracted and transferred to a 5 ml Falcon tube. This sample 
was then frozen at -70 °C until further analysis for plasma glutamine concentrations.
Haematological Analvsis
Blood samples were sent to a health unit laboratory where Complete Blood Counts 
(CBC) were performed within 6 hours using the CELL-DYFF 3500, (Abbott Laboratories, 
Santa Clara, CA). This apparatus discriminates cells according to volume as they induce 
resistance while passing through an electrical potential (Field, 1996). This analysis yielded 
the following dependant variables; total leukocytes, neutrophils, eosinophils, basophils.
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monocytes, and total lymphocyte counts. Following, the CBC the same sample was used for 
analysis of lymphocyte differentials, using the EPICS XL MCL™ (Beckman Coulter, 
Fullerton,CA ) flow cytometeiy. Lymphocyte differentials including T lymphocytes 
(CD3+), T helper (CD3+CD4+), T suppressor/cytotoxic (CD3+CD8+), B lymphocytes 
(CD3-CD19+) and natural killer ( CD3-CD16+56+) cell differentials were analysed using a 
flow cytometer. The CD3+CD4+ and CD3+CD8+ counts were also used to develop a ratio 
score from these two variables (CD4/CD8 ratio). In flow cytometric analysis, cell size is 
determined through the analysis o f its light scatter characteristics, and cell 
immunophenotyping is defined by specific antibodies tagged with fluorescent dyes. Briefly, 
this apparatus detects single cell characteristics (size, granularity, fluorescence) by using an 
optical to electronic coupling system that detects light scatter and fluorescence emissions 
after cell staining (Field, 1996). In order to achieve accurate and reliable results it is 
important that light scatter and fluorescence parameters on a flow cytometer are standardized 
to ensure optimal instrument performance on a daily basis. The use o f fluorospheres to 
standardize light scatter intensity, fluorescence intensity and optimal hydrodynamics 
focussing is widely accepted.
Before analysis could be performed, calibration and compensations procedures were 
conducted. Calibration procedures consisted o f Flow Check, and Flow-Set Flow-Check 
Fluorospheres™ (Beckman Coulter™; PN 6605359) consist of 10 (nominal diameter) 
polystyrene fluorescent microspheres suspended in an aqueous medium containing 
surfactants and preservatives at 1 x 10 "^fluorospheres/ml (nominal concentration). The 
fluorescence emission of the (fye contained within the fluorospheres range from 525 nm to
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700 nm when excited at 488 nm. Flow-Check fluorescence are used to verify instrument 
alignment and fluidics. Flow-Set Fluorospheres™ (Beckman Coulter™; PN 6607007) are a 
suspension of fluorospheres (3.6 //m) used as an aid in optimizing a flow cytometer for 
quantitative analysis of human leukocytes. Each fluorospheres contains a dye which has a 
fluorescent emission ra n ^  of 525 nm to 700 nm when excited at 488 nm. They have a 
uniform size and fluorescence intensity allowing the standardization o f light scatter, 
fluorescence intensity and optimal hydrodynamic focusing instrument settings. Performing 
both Flow-Check and Flow-Set procedures allows adjustment and/or verification of the 
alignment o f the optical and fluidics system of the flow cytometer. In this studyn 500 pi 
sample of Flow-Set Fluorospheres as well as 500 pi of Flow-Check Fluorospheres were 
dispensed into two separate tubes labeled Set and Check, and run to ensure calibration of the 
instrument
Due to the fact that a four color staining procedure was used during this experiment 
compensation measures were also conducted. The CYTO-COMP™ Reagents tat (Beckman 
Coulter™; PN 6607021 ) consist of four two color flourescent reagents comprised of two 
monoclonal antibodies combinations making up each of the reagents. The antibodies are 
labeled with specific combinations of four fluorochrome; FTTC (Fluorescein isothiocyanate), 
RDI (Phycoetythrin), ECD (Phycoerythrin-Texas Red), and PC5 (Phycoerythrin-Cy5).
The CYTO-COMP™ Reagents are used in conjunction with the CYTO-COMP™ Cells 
(Beckman Coulter™; PN 6607023), a preparation of lyophilized human lymphocytes and 
reconstitution buffer used to adjust color compensation settings on a flow cytometer prior to 
multi-color analysis with FTTC, RDI, ECD, and PC5 conjugated monoclonal antibody
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reagents.
Briefly, 100 pi of reconstituted CYTO-COMP™ cells were added to four tubes 
(labeled C l, C2, C3, C4). Then 10 pi of CYTO-COMP™ Reagent 1 (HCT/RDl), 
CYTO-COMP™ Reagent 2 (RDl/ECD), CYTO-COMP™ Reagent 3 (RD1/PC5), and 
CYTO-COMP™ Reagent 4 (ECD/PC5) was added to tube C l, C2, C3, and C4, 
respectively. One millilitre of PBS was then added to each tube and vortexed. After 
calibration and compensation procedures were complete, samples and control cells were 
stained for analysis. 100 pi of IMMUNO-TROL™ whole blood control cells (Beckman 
Coulter™; PN 4238091-E) or sample whole blood from each subject was then added to two 
separate tubes. IMMUNO-TROL™ Control Cells are a positive process control for flow 
cytometry assays for lymphocytes, granulocytes, and monocytes specific antigens and single 
platform absolute counts. This preparation is used to verify the process of sample staining, 
lysing, and analysis. Light scatter, population distribution, fluorescence intensity, and 
antigen density mimic those of whole blood. To the tubes containing IMMUNO-TROL™ 
or test sample whole blood, 5 pi of CYTO-STAT® tetraCHROME™ Reagent CD45- 
FITC/CD4-RD1/CD8-ECD/CD3-PC5 Monoclonal Antibody Reagent (Beckman Coulter™
; PN 6607013) was added to the first tube. Also, 5 pi o f CYTO-STAT® tetraCHROME™ 
Reagent CD45-FITC/CD56-RD1/CD19-ECD/CD3-PC5 Monoclonal Antibody Reagent 
(Beckman Coulter™; PN 6607073) as well as 5 pi o f lOTest® Conjugated CD16-PE 
(ImmimbTechi™;' PN IM1238) was added to the second tube. All sample and control tubes 
were then vortexed gently and incubated for 1S minutes at room temperature. 500 pi o f
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OptiLyse C ® (Beckman Coulter™; PN IM1401) was then added to all sample and control 
tubes, vortexed and allowed to incubate for 10 minutes. OptiLyse C° lysing solution is an 
erythrolytic reagent for lysing human red blood cells following direct immunofluorescence 
staining of whole blood. The final step was to add 500 pi o f PBS (Phosphate Buffered 
Saline) to all samples and control tubes, vortex, and incubate for 20 minutes. These tubes 
were then loaded on the auto loader and analysed on the EPICS XL MCL™ for the 
previously mentioned lymphocyte differentials. See Table 2 for sample preparation during 
flow cytometer analysis.
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Sample Preparation for Flow Cytometer Analysis
Reagents Test Tube Label
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Table 2.
* Add CYTO-COMP reagent, vortex and incubate for 15 minutes, 
t  Add test or control blood, vortex and incubated for 15 minutes.
:  Add OptiLyse C, vortex, and incubation for 10 minutes.
++ Add PBS, vortex and incubate for 20 minutes.
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Plasma Analysis
The determination of glutamine is a two step reaction which first deaminates 
glutamine to L-glutamate (Reaction A) and then continues with the dehydrogenation of the 
L-glutamate to a-ketogluterate accompanied by the reduction of NAD' (Nicotinamide 
Adenine Dinucleotide) to NADH (Reaction B). The conversion of NAD' to NADH is then 
measured spectrophotometrically and is proportional to the amount of glutamate that is 
oxidized, therefore giving the amount of glutamine converted to glutamate in the sample 
(Lund, 1986).
A standard curve was constructed of known concentrations of L-glutamine (see 
Table 3). These preparation were then used in Reaction B. All plasma samples were 
thawed and initially deproteinized with an equal volume of 10 % perchloric acid. These 
were then centrifuged at 3000g for 3 minutes. The sample was then neutralized with 20 % 
KOH and allowed to stand for 10 minutes in an ice bath and then centrifiiged. The 
precipitate was then discarded.
Due to the fact that the plasma samples contain both L-glutamine and L-glutamate 
the samples must be measured for both endogenous L-glutamate and L-glutamate derived 
from the deamination of L-glutamine. Therefore, it is essential that we measure glutamate 
levels before the deamination of glutamine to account for this endogenous source. 
Therefore, two separate tubes were prepared for each sample. Acetate buffer, Glutaminase 
(Sigma^, G8880), water, and plasma test samples were used as the reagents for this reaction. 
See Table 4 for sample preparation for the determination o f glutamate (both endogenous
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Glutamate and deaminated Glutamine). Following this all tubes were incubated at 37 °C 
for 60 minutes.
Dilutions for Glutamine Standard Curve Determination
Glutamine Standard 
Concentration (mM/1)











r 790 10 200 j
O.I 50 740 10 200
02 100 690 10 200
0.3 150 640 10 200
0.4 200 590 10 200 1
0.5 250 540 10 200 1
0.6 300 490 10 200 1
0.7 350 440 10 200 1
0.8 400 390 10 200 1
0.9 1 450 340 10 200 1
I 1 son 79fl in ?nn K
Table 3.
Reaction A - Deamination of Glutamine
1---------------------------------1 ibe
Solutions Endogenous Glutamate Endogenous Glutamate & 
Glut*«iine
10.5 mol/1 Acetate Buffer 200 ul 200 ul
10 kU/1 Glutaminase — 10 ul
Test Sample 250 ul 250 ul
Water 550 ul 540 ul
Table 4.
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Following Reaction A (Deamination of Glutamine), the standard curve preparations 
as well as the two tubes from each sample (one analysed for endogenous glutamate and the 
other analysed for endogenous glutamate and deaminated glutamine) were used for Reaction 
B (Dehydrogenation of Glutamate). As well, Tris-EDTA-Hydrazine Buffer, NAD*
Solution, ADP Solution, and water were used in Reaction B. See Table 5 for sample 
preparation for the Dehydrogenation of Glutamate (Reaction B).




Endogenous Glutamate & 
Deaminated Glutamine
0.1 mol/1 Tris - 2 mmol/1 EDTA- 
0.63 mol/1 Hydrazine Buffer
1 ml 1 ml 1 ml
30 mmol/1 P-NAD* Solution 100 t̂l 100 Ml 100 Ml
100 mmol/1 ADP Solution 10 Ml 10 Ml 10 Ml
Water 390 Ml 390 Ml 390 Ml
Standard* 500 Ml — —
Endogenous Glutamate* — 500 Ml —
Endogenous Glutamate & 
Deaminated Glutamine*
500 Ml
Table 5. * from Reaction A
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®
Absorbance was then read at 339 nm using the Spectronic 1001 Plus (Milton Roy 
Inc., Ivyland, PA) to obtain background reading. Then 20 pi of 1200 kU/1 Glutamate 
Dehydrogenase (L-GLDH) (Roche Biochemicals^, 0127078) was added to each cuvet and 
mixed by inversion an allowed to incubate at room temperature for 40 minutes. Absorbance 
was then read at 339 nm. Background absorbance was subtracted from sample absorbance 
to give net absorbance. The concentration of L-glutamine in a sample was then calculated 
by dividing the absorbance result by 250 pi and multiplied by any dilutions that were made. 
The concentration of glutamine for each subject was then determined by subtracting the 
glutamine concentration derived from the endogenous glutamate from the glutamine 
concentration derived from the endogenous glutamate and the deamination of glutamine.
Saliva Analvsis
Subjects were asked to dribble saliva, unstimulated, into a sterile collection cup. 
Saliva samples were immediately place on ice and frozen at -70°C until further analysis. 
Saliva samples were analyzed for salivary immunoglobulin A (IgA) using an en^m e linked 
immunosorbent assay (ELISA). Briefly, lOpl anti-human IgA (Anti-human IgA, a-chain 
specific, developed in rabbit; Sigma®, 18760) was added to 8ml of coating buffer and mixed. 
lOOpl was then added to all wells of a 96 well microtiter plate. The plate was then incubated 
for at least an hour (this procedure was done the day before, in which case the plates were 
coated and refrigerated overnight). The saliva samples and standards (Purified human
(g)
colostrum IgA 25G0mg/L; Sigma 12636) were taken out o f the freezer to thaw.
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Saliva samples were initially diluted 10 times by adding 9 volumes of water ( 100 pi + 
900pl). lOOpl o f this was then diluted with 900pl water, of which lOOpl was diluted with 
900pl of water. This resulted in three dilutions of xlO, xlO and xlO to give a total dilution 
factor o f 1000. The stock standard was diluted by 25 (50pl + 1200pl water) to give a 
standard of lOOmg/L. This was then diluted by 100 (50pl + 4950pl water) to give a working 
standard of lOOOpg/L. Further dilutions (Table 6) of this working standard were required to 
make the appropriate range (0-500 pg/L).
Dilutions for IgA Standard Curve Determination
IgA Standard 
Concentration (pg/L)
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After incubation the plate was blotted and washed with washing buffer. This was 
repeated 3 times. 150pl of blocking protein (2% Bovine Serum Albumin-PBS solution) was 
then added to all the wells. The plate was then incubated at room temperature for 20 
minutes. The plate was then blotted and washed with washing buffer. This was repeated 3 
times. After this wash,100pl of either standard or saliva was added to wells in quadruplicate. 
The plate was then incubated at room temperature for 90 minutes. After incubation the 
plate was then blotted and washed with washing buffer. This was repeated 3 times. lOpl of 
anti-human IgA peroxidase conjugate (Anti-human IgA, a-chain specific peroxidase 
conjugate Ffab'), developed in goat; Sigma® A4165) was added to 10ml of PBS, mixed and 
lOOpl added to all wells. The plate was then incubated at room temperature for 90 minutes. 
After incubation the plate was blotted and washed with washing buffer. This was repeated 3 
times. lOOpl of o-Phenylenediamine Dihydrochloride (OPD Sigma® Fast Tablets; A4165) 
was then added to each well. The plate was incubated at room temperature for 45 minutes 
before absorbance was measured by dual wave method at 405nm and 650nm using the 
UVmax Kinetic Microplate Reader (Molecular Devices Inc., Sunnyvale,CA).
Supplementation
During the glutamine trials, subjects supplemented their diet with 10 grams of 
L-glutamine (SportPharma™ Inc., Concord, Florida) three times daily, while during the 
placebo trials, subjects supplemented their diet with 10 grams of Inula Pure^ (Ergonomics 
America™, Wyoming) three times daily. This resulted in 30 grams of glutamine or placebo
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being ingested daily by each subject This supplementation regimen continued for a period 
of 14 days. Each subject was given their own supplementation package which contained the 
required doses for the duration of the 2 week supplementation period. All assignments of 
supplementation were allocated on a double-blind basis. During each supplementation 
period subject were asked to keep track of how many supplement doses were missed during 
that period.
Training Log. Dietary Journal and Life Stress Questionnaire Control Factors
All subjects were required to keep a training diary that outlines their daily training 
volume, frequency and intensity for each day throughout the supplementation period. 
Subjects were also required to write down their entire dietary intake for a period of three 
days (two week days and one weekend) before and after each supplementation period. 
Dietary intake was analysed using a computerized software package (FoodWorics*  ̂College 
Edition Version I.O). All subjects also completed a life stress questionnaire (The Social 
Readjustment Rating Scale; Holmes & Rahe, 1967) which computes a stress score 
depending on changes in biological, sociocultural, environmental, and individual factors.
The main purpose for all three o f these measures is to serve as control measure to ensure 
that training, diet and overall stress remain fairly consistent for each individual subject 
throughout the study.
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Statistical Analvsis
Due to the use of a cross-over design data was initially analysed for carry-over 
effects using the procedure outlined by Hills and Armitage (1979). For this procedure 
difference scores before and after the washout period were calculated and analysed using an 
independent sample t-test If no significant differences were found it was deemed that no 
carry-over effect had occurred. To make sure there was no carry-over effect data was 
analysed further using a paired sample t-test between pre-supplementation values (Test 1 vs 
Test 3). This was to insure that pre-test values returned to normal resting values following 
the washout period. If tests for washout revealed that no carry-over effect had^curred, 
data from before and after the washout period were pooled and used for the subsequent 
analysis. Both of these analyses for carry-over effect were used on male and female pooled 
data and on gender specific data. Total leukocytes, neutrophil, basophils, eosinophils, total 
lymphocyte, T lymphocytes (CD3+), B lymphocytes (CD19+), Helper T Lymphocytes 
(CD3+CD4+), Cytolytic T lymphocytes (CD3+CD8+), and natural killer 
(CD3-CD16+CDS6+) cell counts as well as the CD4/CD8 ratio for grouped data was 
analysed using a 2 (pre vs post) x 2 (glutamine vs placebo) repeated measure 2-way 
analysis o f variance (ANOVA). To determine if gender differences played a role in the 
overall analysis, a 2 (pre vs post) x 2 (glutamine vs placebo) x 2 (male vs female) mixed 
plot 3-way ANOVA was utilized. Dietary intake and stress scores for each of the four test 
periods were analysed using a One-way ANOVA. If a significant interaction was present in 
any of the ANOVA results Duncan’s Multiple Range Test was performed to determine 
where the significance lies. Training parameters before and after the washout period were
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analysed using a student’s t-test On all occasions, statistical significance was accepted at a 
level of p< 0.05. Statistical analysis was performed using SPSS® Version 10.0 statistical 
computer package (SPSS® Inc., Chicago, IL) and Stastica (StatSoft® Inc., Tulsa, OK). All 
data is presented as means ± SEM, unless otherwise stated.
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Data was initially analysed for carry-over effects for pooled data on males and 
females. Both the paired t-tests and independent t-tests revealed that there was no significant 
(p<O.OS) different between all variables for male and female pooled data. Furthermore, data 
was analysed for carry-over effects for gender specific data. The paired t-tests on female 
and male data revealed no significant difference (p<0.05) between all variables. Independent 
t-tests on male and female data revealed no significant difference (p<0.05) on all variables 
except for percent monocytes of leukocytes for male specific data (p= 0.046). It was 
concluded from these analyses that no carry-over effect had occurred and therefore data 
from before and after the washout period were pooled and used in the subsequent analysis.
Leukocyte and Lvmohocvte Sub-PoDulations
The mean resting values for leukocyte and lymphocyte sub-populations before and 
after glutamine or placebo supplementation for all subjects is presented in Tables 7 and 8, 
respectively. Separate 2 (treatment; glutamine or placebo) by 2 (time: pre or post) analyses 
o f variance (ANOVA) were conducted on leukocyte and lymphocyte sub-populations. 
Complete ANOVA source tables can be found in Appendix J. For leukocyte count, the 
main effect for supplement and time were not significant (p 0 .0 5 ), however there was a 
trend towards a significant treatment by time interaction, F ( 1,14) = 3.63, g =0.08.
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Analysis of data indicated that there was a trend for mean leukocyte count to increase from 
4.90 ± 0.30 to 5.19 ± 0.34 cells xlO®/L following glutamine supplementation, while there 
was a trend for values to decrease from 5.28 ± 0.30 to 4.97 ± 0.31 cells xlO’/L following 
placebo supplementation, F (1 ,14) = 3.63, g = 0.08. When these changes are expressed as 
a percent change of baseline values, there was a 5.92 % increase and a 5.87 % decrease in 
leukocyte count following glutamine and placebo supplementation, respectively (Figure 4).
A 2 (treatment; glutamine or placebo) by 2 (time: pre or post) ANOVA was 
conducted on neutrophil count For neutrophil count the main effect for treatment was 
significant F ( 1,14) = 5.14, g = 0.04, with glutamine values being higher throughout the 
study period. The main effect for time was not significant, however, there was a trend 
towards a significant treatment by time interaction, _F(1,14) = 3.79, g  = 0.07. Analysis 
indicated that neutrophil count increased from 2.33 ± 0.17 to 2.59 = 0.21 cells xIO’/L 
following glutamine supplementation, and decreased from 2.78 ± 0.21 to 2.49 ±0.19 cells 
xIO’/L following placebo supplementation. Expressed as a percent change of baseline 
values, there was a 11.16 % increase and a 10.43 % decrease in neutrophil count following 
glutamine and placebo supplementation, respectively (Figure 5). There were no significant 
(g > 0.05) main effects or interaction for all other leukocyte and lymphocyte sub-populations 
data (See Figures 6-13).
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Absolute Values for Leukocyte Sub-Populations
Measure (Mean ± SEM)
Leukocyte Count (xlO*/L)
PrcCHu 4.90 ±0.30 PostCHu 5.19 ±0.34
PrePIa 5.28 ±0.30 PostPla 4.97 ± 0 .3 1
Neutrophfl Count (xlO*/L)
PreGhi 2.33 ± 0 .1 7 ' PostGlu 2.59 ± 0 .2 1 '
PrePIa 2.78 ±0.21 PostPla 2.49 ±0.19
Basophil Count (xlO*/L)
PreGlu 0.051 ±0.003 PostGhi 0.051 ±0.007
PrePIa 0.048 ±0.004 PostPla 0.049 ± 0.005
Eosinophil Count (xlO*/L)
PreGlu 0.286 ±0.111 PostGlu 0.310 ±0.136
PrePIa 0.224 ± 0.052 PostPla 0.228 ± 0.058
Monocyte Count (xI(P/L)
PreGlu 0.446 ±0.033 PostGlu 0.437 ± 0.033
PrePIa 0 466 ± 0.038 PostPla 0.433 ±0.025
Lymphocyte Count (xlO*/L) 
PreGlu 1.78 ±0.097 PostGlu 1.80 ±0.117
PrePIa 1.76 ±0.098 PostPla 1.76 ±0.119
Table 7: Immunologic parameters for subjects before and after supplementation with glutamine or placebo. 
Data is presented as grouped data for geiider (n=IS). * Indicates significam (pO.OS) main effect for 







Figure 4: LeokDcyte cell count befioe and after 
suppfcmentiliOBwifliglufnnie or placebo. AH 
viluearee presented as mems^SBd.
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Absolute Values for Lymphocyte Sub-Populations
Measure (Mean ± SEM)
T lymphocyte (CD3+) Count (xiO*/L)
PreGlu 1 J 7 ±  0.087 PostGlu 1.37 ±0.091
PrePIa 1.34 ±0.086 PostPla 1.34 ±0.097
Helper T lymphocyte (CD)+CD4+) Count (xlO*/L)
PreGlu 0.865 ± 0.070 PostGlu 0.852 ±0.069
PrePIa 0.839 ± 0.070 PostPla 0.842 ±0.072
Cytolytic T lymphocytes (CD3+CD8+) Count (xlO*/L)
PreGlu 0.438 ± 0.026 PostGlu 0.447 ±0.031
PrePIa 0.429 ± 0.027 PostPla 0.426 ±0.034
B lymphocyte (CD3-CDI9+) Count (xIO*/L)
PreGlu 0.191 ±0.016 PostGlu 0.203 ±0.022
PrePIa 0.189 ±0.015 PostPla 0.187 ±0.014
Natural Killer Cell (CD3-CD16±CD56±) Couut (xlO*/L)
PreGlu 0.195 ± 0.022 PostGlu 0.217 ±0.032
PrePIa 0.203 ±0.033 PostPla 0.213 ±0.036
Table 8: Immunologie parameters for subjects before and after supplementation with glutamine or placebo. 
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Figuie 5; Neutrophil cell count befixe and after 
supplemeniatxmwiih^utimiBe or placebo. All 
values ate presented as means ± SBd
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Figure 6; Monocyte cell count before and after 
supplementation with glutamine or placebo. All 





Figure 7: Lymphocyte cell count before and after 
suppjemenmiion wfth gtutamine o r  placebo. AD 
values are presented as means = s A d .
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Figure 8; T ^mphocyte (C D 3+) cell count before and 
afiersupplem eniationwiÀghitainineorptaceho. AU 
values are presented as means ±  SEM




Figure 9; He%ier T lympboq^ (CD3+CD4+) ceO 
count before and afiff suppieaaanBtkm widi ÿutamme 
or placebo. AO values are preaentBd as means ± SEM.
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Cytolytic T lymphocyte Count




Figure 10; Cytolytic T lymphocyte (CD3-CD8-) cell count 
before and after supplementation with ghitamme or placebo. 
All values are presented as means ±
CD4/CD6 Ratio
m e u tm im
Pre Post
Test Period
Figure 11: CD4/CD8 ratio before and after 
supplemeniatioa with glutamine or placebo. 
All values arc presented as means =  SEM.
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Figure 12: B Kmphocvte (CD3-CD19+) cell count 
before and after supplwmentation with glutamine or 
placebo. All values are presented as means ± SEM.





Figure 13; Natural killer (CD3-CDIfrK3>S64>) ceO 
count before n d  after aipplBiiiiwwMinniiiittigk»*»!"^ 
orplacdm. AU values ate presented as means ± SEM.
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Due to the fact that the 2-way factorial ANOVA revealed the there were trends in 
the data further investigation was conducted on determine if other factors could account for 
these findings. Therefore data was differentiated by initial glutamine levels (high vs low), 
initial cell counts (high vs low). Furthermore, due to the fact that physiological differences 
in males and females may have an effect on the results, data was also discriminated by 
gender. A 3-way ANOVA on this data indicated that there was a significant effect of gender 
on the results. Therefore separate 2 (treatment; glutamine or placebo) by 2 (time: pre or 
post) by 2 (gender, male or female) ANOVA were conducted on the data'.
Absolute leukocytes, neutrophils, and percent neutrophils o f leukocytes were found 
to have a significant effect by gender (Table 9). All other immunological parameter were 
not significantly different (g >0.05) when differentiated by gender.
Absolute Values for Leukocyte Sob-Populations Differentiated by Gender
Leukocyte Count (xlO*/L) 
Females Males
PreGlu 4.90 ±0.49 PostGlu 5.57 ±0.55' PreGlu 4.91 ±0.45 PostGlu 4.94 ±0.45
PrePIa 5.47 ±0.55 PostPla 4.75 ± 0 5 0 ' PrePIa 5.15 ±0.39 PostPla 5.11 ±0.41
Neutrophil Count (xl(P/L) 
Females Males
PreGlu 112 ±0.27 PostGlu 183 ±0.33' PreGlu 147 ±0.22 PosiGlu 143 ±027
PrePIa 189 ±0.34 PostPla 122 ±0 JO ' PrePIa 170 ±0.28 PostPla 167 ±025
Percent Neutrophils of Leukocytes 
Females Mates
PreGlu 44.25 ±180 PostGlu 51.37 ± 3 2 9 ' PreGlu 50.13 ±128 PostGlu 48.61 ±168
PrePIa 5157 ±3.06 PostPla 47.03 ± 1 7 0 ' PrePIa 51.86 ±149 PostPla 52.04 ±221
Table 9: Immunologic parameters for subjects before and after supplementation with glutamine or placebo. 
Data is di&rentiated by gender (Females n=6; Males n=9). * Indicates a significant (p<O.OS) difference 
compared to baseline. AH values are presented as means ± SEM.
'Although significant findmgs were found it should be noted that this analysis was limited 
by relatively small and unequal numbers per cell (Females n=6. Males n=9).
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For leukocyte count differentiated by gender the 2 (time; pre or post) by 
2 (treatment; glutamine or placebo) interaction was significant, (g <0.05). More importantly 
the 2 (gender male or female) by 2 (time; pre or post) by 2 (treatment; glutamine or 
placebo) interaction for leukocyte count was significant, E ( 1,13) = 5.69, g  = 0.03, 
therefore Duncan’s post hoc tests were performed to determine the nature o f the interaction. 
There was an increase for females receiving glutamine from 4.90 ± 0.49 to 5.57 ± 0.55 ceils 
xlO’/L, g <0.05, while those receiving placebo decreased from 5.47 ± 0.55 to 4.75 ± 0.50 
cells xlO^/L, g <0.05. Values for male subjects receiving glutamine showed virtually no 
change from 4.91 ± 0.45 to 4.94 ± 0.45 cells xIO®/L, g >0.05, while those on placebo 
changed from 5.15 ± 0.39 to 5.11 ± 0.41 cells xl0*/L, g >0.05. When these changes are 
expressed as a percentage change of baseline values, there was a 13.67 % increase and a 
13.16% decrease in female leukocyte count following glutamine and placebo 
supplementation, respectively. Males showed a 0.61 % increase and 0.78 % decrease in 
leukocyte count following glutamine and placebo supplementation, respectively (Figure 14). 
There were no significant main effects or other interaction for leukocyte count data when 
differentiated by gender (g >0.05).
For neutrophil count differentiated by gender the 2 (time; pre or post) by 2 
(treatment; glutamine or placebo) interaction was significant, (g <0.05). More importantly 
the 2 (gender male or female) by 2 (time; pre or post) by 2 (treatment; glutamine or 
placebo) interaction for neutrophil count was significant, F (1,13) = 9.87, g = 0.008), 
therefore Duncan’s post hoc tests were performed to determine the nature o f the interactioiL 
Absolute neutrophil count significantly increased for females receiving glutamine from 2.12
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± 0.27 to 2.83 ± 0.33 cells xlO’/L, g <0.05, while those receiving placebo decreased from 
2.89 ± 0.34 to 2.22 ± 0.30 cells xlO’/L, g  <0.05. Values for males subjects receiving 
glutamine decreased from 2.47 ± 0.22 to 2.43 ± 0.22 cells xIO’/L, g <0.05, while those on 
placebo decreased from 2.70 ± 0.28 to 2.67 ± 0.25 cells xIO’/L, g  <0.05. When these 
changes are expressed as a percent change of baseline values, there was a 33.49 % increase 
and a 23.18 % decrease in female leukocyte count following glutamine and placebo 
supplementation, respectively. Males showed a 2.99 % decrease and 0.19 % decrease in 
leukocyte count following glutamine and placebo supplementation, respectively (Figure 15). 
It should be noted that the treatment effect seen in the female subject may partially be due to 
the groups varying pretest values before supplementation and not solely due to the 
supplementation treatment There were no significant main effects or other interaction for 
neutrophil count data when differentiated by gender (g >0.05).










Figure 14; Absolute leukocyte count dlffBrentiated by gender before and after 
supplementation with glutamine or placebo. All values are presented as means 
±  SEM. "Indicates a significant (p^.OS) rfifforence compared to baseline values.
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Neutrophil Count by Gender
Females Males
Pre Post
Test Period Test Period
Figure 15; Absolute neutrophil count differentiated by gender before and after 
supplementation with glutamine or placebo. All values are presented as means 
£ SEM. "Indicates a significant difference compared to baseline values.
Proportion of Cell Tvne
The mean resting values for the proportion of leukocyte and lymphocyte sub­
populations are shown in Tables 10 and 11, respectively. A 2 (treatment: glutamine or 
placebo) by 2 (time: pre or post) on percent neutrophils of leukocytes. For percent 
neutrophils the main effect for treatment was significant (g <0.05), with glutamine values 
being higher throughout the sturfy period. The main effect for time was not significant, 
however, there was a trend towards a significant treatment by time interaction.
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F ( 1 ,14) = 2.87, g = 0.11. Analysis ofdata indicated that there was a trend for the 
glutamine supplemented group to increase the proportion of neutrophils from 47.78 ±1.87 
% to 49.71 ± 2.03 %, while the placebo group decreased from 52.14 ± 1.86 % to 50.04 ± 
1.77 %. When these changes are expressed as a percent change of baseline, there was a 
4.04 % increase and a 4.03 % decrease in leukocyte count following glutamine and placebo 
supplementation, respectively as shown in Figure 16. There were no significant main 
effects or interactions for all other proportion o f cell type data (g >0.05).
Proportion of Cell Type (Leukocyte Sub-Popuiatioas)
Measure (Memo ± SEM)
Percent Neutrophib of Leukocytes
PreGlu 47.78 ±1.87* PostGlu 49 71 ± 2.03*
PrePIa 52.14 ±1.86 PostPla 50.04 ±1.77
Percent BasophOs of Leukocytes
PreGlu 1.05 ±0.06 PostGlu 0,99 ±0.11
PrePIa 0.92 ±0.05 PostPla 1.00 ±0.07
Percent Eosinophfls of Leukocytes
PreGlu 5.11 ±1.66 PostGlu 5.28 ±1.99
PrePIa 3.97 ±0.75 PostPla 4.18 ±0.88
Percent Monocytes of Leukocytes
PreGlu 9.17 ±0.53 PostGlu 8.57 ±0.52
PrePIa 8.93 ±0.64 PostPla 8.96 ±0.54
Percent Lymphocytes of Leukocytes
PreGlu 36.89 ±1.50 PostGlu 35.47 ±1.92
PrePIa 34.05 ±1.88 PostPla 35.83 ±1.84
Table 10; Immunologic parameters for subjects before and after supplementation whh glutamine or placebo. 
Data is presented as grouped data for gender (n=I5). * Indicates significant (p<0.05) main effect for 
supplementation, with glutamine values being higher throughout the study. All values are presented as 
means ±  SEM.
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Percent Neutrophils
Test Period
Figure 16; Proportion o f neutrophils o f  leukocyte before 
and after supplementation with ^utamine or placebo.
AD values are presented as means ±  SEM
Proportion of Cell Type (Lymphocyte Sub-Populations)
Measure (Mean ± SEM)
Percent of T lymphocytes (CD3) of Lymphocytes
PreGlu 76.67 ±1.67 PostGlu 76.25 ±1.76
PrePIa 76.11 ±1.75 PostPla 75.86 ±1.73
Percent CD3+CD4+ of Lymphocytes
PreGlu 47.94 ±2.32 PostGlu 47.38 ±2.25
PrePIa 47.26 ± 2 2 8  PostPla 47.49 ±2.21
Percent CD3+CD8± of Lymphocytes
PreGlu 24.79=1 03 PostGlu 25.05 ±1.00
PrePIa 24.65 ±1.12 PostPla 24.30 ±1.05
CD4/CD8 Ratio






Percent CD19 of Lymphocytes
PreGlu 10.95 ±0.82 PostGlu 11.21 ±0.78
PrePIa 10.89 ±0.79 PostPla 10.83 ±0.76
Percent CD3-CDI6±CD56± of Lymphocytes
PreGlu 11.23 ±1.21 PostGlu 11.85 ±1.46
PrePIa 11.51 ±1.85 PostPla 11.89± 1.52
Table 11; Immunologic parameters for subjects before and after supplementation with glutamine or placebo. 
Data is presented as grouped data for gender (n=15). AD values are presented as means ± SEM
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For percent neutrophils differentiated by gender the 2 (time: pre or post) by 2 
(treatment: glutamine or placebo) interaction was significant, (g <0.05). More importantly 
the 2 (gender male or female) by 2 (time: pre or post) by 2 (treatment glutamine or 
placebo) interaction for leukocyte count was significant, F (1,13) = 21.51, g = 0.001, 
therefore Duncan’s post hoc tests were performed to determine the nature of the interaction. 
Post hoc analysis indicated that percent neutrophils significantly increased for females 
receiving glutamine from 44.25 ± 2.80 % to 52.57 ± 3.06 %, g <0.05, while values for those 
subjects receiving placebo decreased from to 47.03 ± 2.70 % to 51.37 ± 3.29 %, g <0.05, as 
shown in Table 9. Percent neutrophil values for males subjects receiving glutamine 
decreased from 50.13 ± 2.28 % to 48.61 ± 2.68 %, g >0.05, while values for those subjects 
receiving placebo increased slightly from 51.86 ± 2.49 % to 52.04 ± 2.21%, g >0.05. When 
these changes are expressed as a percentage change of baseline values, there was a 16.03 % 
increase and a 10.65 % decrease in females neutrophil percentage following glutamine and 
placebo supplementation, respectively. Male subjects showed a 2.99 % decrease and 
0.19% increase in neutrophil percentage following glutamine and placebo supplementation, 
respectively (Figure 17). It should be noted that the treatment effect seen in the female 
subject may partially be due to the groups varying pretest values before supplementation and 
not solely due to the supplementation treatment There were no significant main effects or 
other interaction for percent neutrophils data when differentiated by gender (g >0.05).
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Figure 17; Proportion of neutrophil differentiated by gender before and after 
supplementation witti glutamine or placebo Ail values are presented as means 
±  SEM. "Indicates a significant (p<0.05) difference compared to baseline values.
Saliva leA. & Plasma Glutamine
Saliva Immunoglobulin A (IgA) and plasma glutamine concentrations are presented 
in Table 12. For saliva IgA, the main effects for treatment and time as well as the 
interaction were not significant (g >0.05) (Figure 18). For plasma glutamine, the main 
effects for treatment and time as well as the interaction were not significant (g >0.05) 
(Figure 19).
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Saliva IgA and Plasma Glutamine
Measure (Mean ± SEM)
Saliva IgA (mg/l)
PreGhi 175.44 ±18.97 PostGu 179.18 ±27.82
PrePla 154.19 ±19.60 PostPla 176.15 ±18.75
Plasma Glutamine (/zmol/l)
PreGhi 681.11 ±28.22 PostGht 688.84 ± 56.52
PrePla 635.74 ±35.22 PostPla 654.57 ±34.31
louic 1^. aauva wm puunui ^uuiniuic cuuwcnuauuu^ lut midjcgu ociurc anu ancr suppicmcwawun ' 







Pre _   ̂ , Post
Test Penod
Figure 16: Saliva IgA concentration before and after 
supplementation with glutamine or placebo. All 
values are presented as means ±SEM.
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Figure 19; Plasma glutamine concentration before 
and after suppkm entation with ghitamine or placebo. 
All values are presented as means ±  SEM.
Control Factors (Endurance Training. Psvcholopcal Stress. & Nutritional Intake)
Endurance training, psychological stress, and nutritional intake are presented in Table 
13. There was no significant change (p >0.05) in endurance training durii^ the two test 
periods before and after washout There was also no significant difference (p >0.05) in 
psychological stress and 3 day nutritional intake values during the four different testing 
periods.
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Control Factors
Measure (Meant SEM) Statistics
Endurance Training (Kn/wk) t = - 0 44
Pre Washout 64.07 ±3.20 Post Washout 65.37 ±4.51 df (14)
p = 0.67
Psychological Stress Score F = 0.44
Period 1 57.70 ±11.03 Period 2 41.33 ± 10.68 df (3.59)
Period 3 46.93 ± 12.43 Period 4 51.53 ±1118 p = 0.73
Caloric Intake (kcal/day) F = 0.50
Period 1 3043 ±247 Period 2 2692 ±204 df (3,59)
Pwtod 3 2854 ±241 Period 4 2714 ±224 p = 0.69
Carbohydrate Intake (grams/day) F = 0.24
Period 1 429.5 ±38.9 Period 2 385.7 ±31.3 df (3.59)
Period 3 405.2 ±37.5 Period 4 405.2 ±38.3 p = 0.87
Protein Intake (grams/day) F = 0.41
Penod 1 115.8 ±116 Period 2 100.8 ± 9.3 df (3.59)
Penod 3 109.4 ± 6.8 Period 4 105.6 ±10.4 p = 0.75
Fat Intake (grams/day) F = 0.94
Penod I 98.0 ±8.5 Penod 2 85.7 ±7.5 df (3.59)
Period 3 89.7 ±8.4 Period 4 79.5*7.4 p = 0.43
Iron Intake (mg/day) F = 0.63
Period 1 216 ± 1 2 Period 2 13.8 ± 1 3 df (3.59)
Period 3 23 4 ± 1 8 Period 4 27.5 ±3.4 p = 0.60
Magnesium Intake (mg/day) F = 0.31
Penod 1 439.1 ±41.8 Period 2 403.3 ±37.7 df (3.59)
Penod 3 396.2 ±40.3 Period 4 389.7 ±38.1 p = 0.82
Zinc Intake (mg/day) F = 0.12
Period 1 14.3 ±1.6 Period 2 13.5 ±1.5 df (3.59)
Period 3 14.7*5.2 Period 4 13.7 ±0.7 p = 0.95
Vitamm A Intake (RE/day) F = 0.52
Period 1 1310*188 Period 2 1349 ±220 df (3.59)
Period 3 1346 ± 146 Period 4 1635 ±264 p = 0.67
Vhamin C Intake (mg/day) F = 0.36
Penod 1 345.5 ±914 Period 2 300.5 ±58.0 df (3.59)
Period 3 246.2 ±60.3 Penod 4 279.6±6l.l p=0.78
Vhamin E Intake (mg/day) F = 0.72
Period 1 9.1 ±1.5 Period 2 7.2 ±1.1 df (3.59)
Period 3 6.7±0.6 Period 4 8.5 ±1.6 p = 0.55
Vhamin B6 Intake (mg/day) F = 0.53
Period 1 3.07 ±0.27 Period 2 186 ±0.36 df (3.59)
Period 3 196 ±0.28 Period 4 3.52 ±0.60 p = 0.67
Table 13 :Canm>lâctor date (nutiitianal intake, psychological stress, and training) for subjects befixe each of the 
four difibrent test petiodstfarougbout the study. DÜtaé presented as giouped data for geiMjer(i^lS). All values 
are presented as means ±  SEM.
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Chapters
DISCUSSION
Recent research has suggested that high intensity long duration exercise may be 
detrimental to immune function and lead to a higher rate of infection in athletes (Nieman and 
Pedersen, 1999). One possible mechanism for the decreased immune function and increased 
infection rates associated with intense long duration exercise and overtraining is a decrease 
in plasma glutamine concentrations. Recent studies have shown that athletes participating in 
high intensity exercise or those athletes who are in a state o f overtraining have lower plasma 
glutamine concentrations than other athletes and control subjects (Parry-Billing et al., 1992; 
Rowbottom, et al., 1995; Castell et al., 1997).
Glutamine is the most abundant amino acid in the blood and in the muscles and is the 
primary fuel for rapidly dividing cells, including the cells o f the immune system. In 
particular, glutamine is important for the proliferation o f lymphocytes and macrophages, and 
therefore may be important in the maintenance of proper immune function (Ardawi & 
Newsholme, 1985; Hall, et al., 1996; Walsh, et al., 1998).
During times of metabolic stress such as when athletes are overtrained or during 
critical illnesses such as cancer, the body may require between 20-40 grams of glutamine to 
maintain proper homeostasis (Krebs, 1935). Due to the fact that a normal mixed protein diet 
has been estimated to provide less than 10 grams per day, an exogenous source of glutamine 
may be appropriate (Hall et al., 1996). Therefore, glutamine supplementation may be a 
useful practice for those individuals experiencing impaired immtme function due to various 
physiological stresses (Chandra, 1995).
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Collectively, this research suggests that glutamine supplementation may be beneficial 
to individuals experiencing catabolic and metabolic stress. Therefore, the intent of this study 
was to examine the effect of oral glutamine supplementation on resting blood and saliva 
immune parameters in endurance trained athletes.
Currently there has been a handful o f studies examining the role o f glutamine 
supplementation on the immune function o f athletes following acute exercise 
(Castell et al., 1997; Castell & Newsholme, 1997; Castell, Poortmans, & Newsholme, 1996 
Rohde, Asp, et al , 1998; Rohde, MacLean, et al., 1998; Walsh et al., 2000). However, to the 
knowledge of the author, this is the first study of its kind to examine the effect of oral 
glutamine on resting immune parameters of athletes participating in chronic, high intensity, 
endurance training. Furthermore, this is the first study to use a therapeutic dose o f 30 grams 
daily in an athletic population. This dosage, which is commonly used in a hospital setting 
was administered for fourteen consecutive days.
The main finding of this study was that a glutamine supplementation regimen of 30 
grams daily for 14 days resulted in an increase in leukocytes, neutrophils and percent 
neutrophils in female athletes but did not have any positive effect on any immune parameters 
of male athletes. When data was differentiated by gender the trends observed in absolute 
leukocyte count, absolute neutrophil count and precent neutrophil showed a significant 
gender effect When compared to baseline values, absolute leukocyte count significantly 
increased for females endurance athletes receiving glutamine by 13.67 % and decreased by 
13.16% following placebo supplementatiorL Absolute leukocyte counts for male endurance 
athletes showed virtually no change with values increasing by 0.61 % following glutamine
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supplementation and decreasing by 0.78 % following placebo supplementation.
Absolute neutrophil count significantly increased for females receiving glutamine by 
33.49% and decreased by 23.18% following placebo supplementation. Again, males 
showed virtually no change with neutrophil counts increasing by 1.62 % following glutamine 
supplementation and decreasing by 1.11 % following placebo supplementatiorL Perçoit 
neutrophil values significantly increased for females receiving glutamine by 16.09 %, viiiile 
those subjects receiving placebo decreased by 10.54 %. Male subjects showed non 
significant increases by 3.03 % and 0.35 % following glutamine and placebo 
supplementation, respectively.
There was also a significant main effect for supplementation in neutrophil cell count 
and percent neutrophils, with glutamine values being higher through the study. Furthermore, 
there was a trend for resting levels for leukocytes and neutrophils as well as percent 
neutrophils to increase over the period of study, while placebo supplementation resulted in a 
decrease in these variables. The results from this study show that when data was pooled and 
not differentiated for gender there was a trend for absolute leukocyte, absolute neutrophil 
and percent neutrophil values to increase following glutamine supplementation, while 
placebo supplementation resulted in a decrease from resting values. There was a 5.92 % 
increase in leukocyte count following glutamine supplementation coupled with a 5.87 % 
decrease in leukocyte count following placebo supplementation. Neutrophil count followed 
a similar trend with glutamine supplementation resulting in an 11.16% increase while 
placebo supplementation resulted in 10.43 % decrease. Also, percent neutrophils followed 
this same trend with glutamine supplementation resulting in an 4.04 % increase while the
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placebo group showed a 4.03 % decrease.
This study has demonstrated that endurance trained female athletes participating in 
chronic endurance exercise may benefit from glutamine supplementation. It is unclear why 
these changes in immune parameters were only seen in females and not in males, but it is 
possible that hormonal differences may have played a role in the efficacy o f glutamine 
supplementation during chronic, high intensity, endurance training. However, there is a lack 
o f research to support this hypothesis.
The results from this study on male athletes are in agreement to those of Castell et al. 
(1997) and Rohde, Asp, et al. (1998) who found that male athletes who supplemented with 
glutamine following a marathon had no effect on their leukocyte and lymphocyte 
distributioTL These results are also in agreement to findings by Rohde, MacLean, et al.
( 1998) who found that glutamine supplementation had no significant effect on circulating 
lymphocytes after male subjects performed three bouts of cycle ergometry lasting 60,45, and 
30 minutes at 75 % VO;max, separated by two hours rest Although glutamine 
concentrations were higher in the glutamine supplemented group there was no difference in 
circulating lymphocytes between groups. These findings are in agreement with Walsh et al. 
(2000) who found that glutamine supplementation had no effect on the neutrophil function of 
male subjects following a 2 hour cycling bout at 60 % VO^max.
The results of this study from female athletes are in agreement with findings from 
clinical trials with critically ill individuals. Clinical investigations with cancer patients have 
found positive results following glutamine supplementation. Yoshida et al. (1998) found that 
glutamine supplementation in patients with esophageal cancer receiving chemotherapy
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prevented a reduction in the lymphocyte count, T-lymphocyte count, and B-lymphocyte 
count compared to those not receiving glutamine after 7 days. The authors suggest that oral 
glutamine supplementation protects lymphocytes in patients with advanced esophageal 
cancer receiving radiochemotherapy. Furthermore, Ziegler et al. (1998) found that bone 
marrow transplant patients, supplemented with glutamine as part o f their parenteral 
nutrition, had an increased lymphocyte count, greater T-lymphocyte count, greater CD4, and 
increased CD8 count compared to those receiving standard parenteral nutrition formulas.
The authors suggest that glutamine supplementation may support lymphocyte recovery after 
bone marrow transplants. Some other authors have also found that glutamine 
supplementation results in positive effects on immune function following exercise. Castell, 
et al. ( 1996) had subjects supplement with either glutamine or a placebo after a marathon or 
ultra-marathon. The results indicated that subjects reporting no infections was significantly 
higher (80.8 ± 4.2 %, p< 0.001) following glutamine supplementation compared to placebo 
supplementation (48.8 ± 7.4 %). It has also been reported that athletes receiving a 
glutamine drink following a marathon or ultra-marathon had a significantly higher CD4/CD8 
ratio then athletes receiving a placebo drink (Castell & Newsholme, 1997).
The contrasting results reported in the literature and in this present study may be due 
to a  difference in dose and length of the supplementation period. A larger dose and longer 
supplementation period may have provided ample glutamine to significantly affect immune 
cell counts in the female athletes. It is also possible that a one bout exercise protocol 
followed by a single day of supplementation that has been used in previous research may not 
have been sufBcient to cause decrements in immune parameters that can be alleviated by
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glutamine supplementation. Furthermore, the chronic training undertaken by the females in 
this study may have had a more detrimental effect on their immune system as seen by the 
decrease in both leukocyte and neutrophil count over the two week period during placebo 
supplementatioiL This decrease was not evident when females were provided with 
supplemental glutamine. In this case not only did glutamine significantly correct or stop the 
decline in overall leukocyte and neutrophil counts in the female athletes, but it also led to an 
increase above resting levels.
An interesting finding discovered during the review of literature revealed that there 
was a gender bias in the previous studies examining the effect o f glutamine supplementation 
on the immune system. Previous research (Castell et al., 1997; Rohde, Asp, et al.,1998; 
Rohde, MacLean, et al., 1998; Walsh et al., 2000) that had found no positive results on 
immune function following glutamine supplementation had used only male subjects as part 
of their design. However, the two previously reported studies (Castell & Newsholme, 1997; 
Castell, et al., 1996) that found significant positive effects in immune function following 
glutamine supplementation utilized both male and female subjects, a lth o t^  these findings 
were not examined for gender differences. It is unclear if  these findings are due to 
coincidence or due to a causal relationship. However, these current findings support 
previous findings indicating that female subjects may cause the majority o f the changes seen 
in immune parameters following glutamine supplementation, whereas males do not 
experience any changes.
Resting plasma glutamine levels were not significantly different after 
supplementation with glutamine or placebo and remained at physiologically normal resting
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levels (500-700//mol) (Castel and Newsholme, 1997; Walsh et al., 1998). It is suggested 
that even though resting plasma glutamine levels were not affected by glutamine 
supplementation in this study, glutamine supplementation may have corrected the post­
exercise fall in plasma glutamine following exercise. However the non-responsive change 
seen in glutamine profiles is not surprising considering the time course for plasma glutamine 
following glutamine supplementation. Plasma glutamine concentrations will increase sharply 
after administration, reaching peak values within 30 minutes and remain elevated for 1-2 
hours and then return back to resting values within 3 hours (Castell and Newsholme, 1997). 
Considering that our subjects were asked to provide a blood sample 8-10 hours following 
their final glutamine dose, the results found in this study are not surprising.
Therefore, although post-exercise glutamine measures were not possible it is 
suggested that glutamine supplementation corrected post-exercise changes in plasma 
glutamine. This correction in plasma glutamine levels may have then led to increased resting 
level o f leukocytes and neutrophils in female athletes. Two possible explanations for these 
changes are evident First glutamine supplementation may have decreased the fall in plasma 
glutamine during actual training bouts. Second, changes in plasma glutamine may not reflect 
intramuscular glutamine stores following long term supplementation when plasma glutamine 
stores are at the physiologically high range.
Although this present study has shown that glutamine supplementation provided to 
females participating in chronic, high intensity, endurance training improved resting 
leukocyte and neutrophil counts, further research should be conducted to determine the 
mechanism for this change. Future considerations should include determining the gender
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differences associated with these present changes. Recommendations include; 1 ) to 
determine the pattern o f plasma glutamine over the menstrual cycle; 2) to determine if 
plasma glutamine values show a correlation with hormone profiles; 3) to determine if a 
causal relationship exists between sex hormone profiles and plasma glutamine levels 
following supplementation. Furthermore, it is suggested that future research should include: 
I ) an examination and comparison o f intramuscular glutamine stores compared to plasma 
concentrations; 2) plasma glutamine time analysis at various points following specific 
exercise bouts, 3) examination of the efficacy of glutamine supplementation on the immune 
system of athletes participating in higher level of exercise (e.g. triathletes, cross-country 
skiers, etc.), and in different type o f exercise training (e.g. anaerobic type exercise); 4) 
replication of this present design with a larger sample size o f both male and female athletes.
In summary, the results of this present study show that glutamine supplementation 
at a dose of 30 grams daily for a period of fourteen days, not only stopped the decline in 
leukocyte and neutrophil count experienced by the placebo supplemented group, but also 
resulted in a rise in these variables above baseline levels in female subjects. Furthermore, 
the changes in the leukocyte and neutrophil counts seen in female athletes were not evident 
in male athletes. This may suggest that glutamine may play a role in other systems, such as 
the endocrine system, which can ultimately affect immune function. Therefore glutamine 
supplementation may be an effective way of improving leukocyte and neutrophil count in 
female athletes after intense prolonged exercise or those experiencing overtraining 
syndrome. Further research is required to determine if  glutamine supplementation will 
correct the inununosupfxessive state o f female athletes during chronic endurance training.
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Appendix A - Cover Letter
‘The Effect of Oral Glutamine Supplementation on Immune 
Parameters in Endurance Trained Athletes”
Dear Participant
I would like to begin by thanking you for considering to be a participant in this 
research study. Furthermore, feel free to approach me at anytime if  you have any 
questions or concerns related to this study.
The intent of this research project is to evaluate the role o f dietary glutamine 
supplementation on the immune system of endurance trained athletes. It is being 
conducted by the School o f Kinesiology, Lakehead University in collaboration with the 
Northwestern Ontario Regional Cancer Centre and the University o f Ottawa Hospital 
Research Institute, Centre for Molecular Medicine. Very little is known about glutamine’s 
effect on the immune system of athletes, however research with critically ill patients has 
shown that glutamine supplementation is beneficial.
Potential volunteers will be screened for continued participation in the study. 
Criteria tor inclusion include health status, and personal training habits. Therefore, all 
subjects will be required to complete a preliminary questionnaire, witich outlines your 
training habits and any past or current medical problems. In order for the researcher to 
achieve accurate responses from this questionnaire, the specific selection criteria will not 
be disclosed. After completion o f the preliminary questionnaire those individuals that fit 
the specific criteria will be asked to volunteer and those who don’t will have fulfilled their 
role in this research project
Those individuals fitting the specific selection criteria will continue with the 
procedures outlined below. These procedures will allow us to assess the role o f glutamine 
on athletes immune system. During the study you will be asked to complete a 
questionnaire outlming your physical training habits, a life stress questionnaire, and a 3 
day dietary intake log on four separate occasions. You will also be required to provide a 
blood and saliva sample on four separate occasions during this study. The utmost care and 
safety will be taken when handling blood and saliva and will be performed by a certified 
phlebotomist We also ask that you maintain your regular training, and dietary schedule 
throughout the entire study. The entire stutty will last a period o f two months, however 
you will only be required to visit with the researchers (the laboratory) for approximately I 
hour on 4 separate occasions. Throughout this two month period you will supplement 
your diet with two different treatments (glutamine and a placebo). You will supplement 
for two weeks will glutamine and two weeks with a  placebo. These two supplementation 
periods will be separated by a one month washout period, consisting o f no treatment 
Glutamine is a natural occurring amino acid found in various plant and animal sources, 
and has been shown to have no known side effects when taken as an oral or intravenous
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solution in various populations. The placebo will consist o f a powder which is use as a 
sugar substitute.
As a volunteer, you have the right to refuse any test and to withdraw from the study 
at any time. All the information gathered during this study will remain confidential 
through the use o f a coding system. No reference to any participant will be made at 
anytime in any report o f the results. The data will be securely stored by Joe Quadrilatero 
and Dr. Ian Newhouse within the Faculty o f Kinesiology at Lakehead University for seven 
years. However, the findings o f this project will be made available to you at your request 
upon completion o f the project
If you have any questions concerning the study, I may be reached by phone at home 
(807) 577-9541 or at work (807) 346-7815. I may also be reached by means o f email at 
{quadrilJ@air.onca).
Thank you for your cooperatiotL
Sincerely,
Principal Investigator Joe Quadrilatero 
Advisors: Dr. Ian Newhouse and Dr. Norm LaVoie
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Appendix B - Consent Form
1. I _________________________________ consent to take part in a study which
examines the effect o f oral glutamine supplementation on the immune system of 
endurance trained athletes and understand that the entire study will last a period of 
8 weeks.
2. I agree to attend an information session, at which time all pertinent information 
regarding my participation in the study will be outlined, and all questions and 
concerns will be addtessed. Also, instructions on how to properly preform the 
following will be provided;
1) recording daily nutritional intake
2) recording training routine
3) completing life stress questionnaire
4) administering treatment (glutamine or placebo)
3. I agree to record all my daily nutritional intake for 3 days on four separate
occasions (before and after each of the two supplementation periods). That is, 
everything that 1 consume (food and drink) will be written down in a log book 
according to the procedures outlined in the information session. Furthermore, I 
agree to maintain my regular diet through the duration of the stucty.
4. I agree to complete a training log during each o f the two supplementation periods
outlining my daily routine according to the procedures outlined in the information 
session. Furthermore, I agree to maintain my regular training volume through the 
duration o f the stu<ty.
5. I agree to complete a life stress questionnaire (The Social Readjustment Rating
Scale) on four separate occasions (before and after each o f the two 
supplementation periods) according to the procedures outlined in the information 
session.
6. 1 agree to provide a blood and a saliva sample on four separate occasions (before 
and after each o f the two supplementation periods). I understand that the blood and 
saliva samples will be taken by a certified phlebotomist which will perform the 
testing in a safe and sterile environment I am aware that the chance o f infection or 
serious complications is minimal, however some individuals may experience a 
feeling o f l i^ t  headedness upon removal o f blood. I also, understand that there 
may be some slight bruising and discomfort from the needle, but should disappear 
within a few days.
7. I agree to participate in two separate supplementation periods each lasting a
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duration of 2 weeks according to the procedures outlined in the information 
session. One supplementation period will involve the addition o f glutamine to my 
regular diet while the other supplementation period will involve the addition of a 
placebo (Inula Pure*-a sugar substitute) to my regular d ie t I understand that both 
supplementation periods will be separated by a 4 week period that involves no 
treatment (maintain regular diet). I am also aware that the treatment (glutamine or 
placebo) will be administered in a random fashion, therefore I will not be aware o f 
which treatment I am receiving during each supplementation period.
8. I understand that as a volunteer, I have the right to refuse any test and to withdraw 
from the study at any time. All the information gathered during this stucfy will 
remain confidential through the use o f a coding system. No reference to any 
participant will be made at anytime in any report of the results. The data will be 
securely stored by Joe Quadrilatero and Dr. Ian Newhouse within the Faculty of 
Kinesiology at Lakehead University for seven years. However, the findings o f this 
project will be made available to me at my request upon completion o f the project 
I understand that if  I should have any questions concerning the study, I should 
contact Joe Quadrilatero by phone at home (807) 577-9541, at work (807) 346- 
7815 or by means o f email at {quadrUj%xir.on.ca\
Signature o f Participant Date
Signature o f Wimess Date
9. I have explained the nature o f the study to the participant and believe he/she has
understood it fully.
Signature o f Researcher Date
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Appendix C - Prelim inary Questionnaire
Name______________________  Age______ Sex________
For all questions please be as specific as possible. Thank You.
I. What type of endurance training are you currently participating (eg. cross-country 
running, track, cross-country skiing) ?
2. On average, how many days per week do you participate in endurance type training?
3. On average, how many kilometers or miles do you perform during your endurance 
training per week?
4. On average, what is the duration (minutes) o f your endurance training sessions?
S. On average, at what intensity are your endurance training sessions ? (eg. 50% o f max, 
75% o f max).
6. Do you have any injuries or medical illnesses that have affected your training in the 
past? Ifyes, how did it affected your training?
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7. Periodically throughout the stu(fy you will be asked to provide a blood/saliva samples. 
Please list any events/competitions (or other obligations) during the months o f September, 
October, November that require you to be away from Thunder Bay and that may affect 
your ability to provide samples ?
8. Have you ever supplemented with glutamine?
9. Are you currently taking any type o f nutritional supplement (eg. vitamins, protein drink, 
creatine etc.) ?
10. Are you current participating in any other type o f physical activity during an average 
week (eg. weight training, squash, soccer etc.)? Please describe in detail the time spent 
on these activities on an average week.
11. Will there be any changes to your training routine Aom now until mid November?
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Appendix D - Reagents for Flow Cytometer Analysis
1) Flow-Check Fluorospheres™ (Beckman Coulter™; PN 6605359)
2) Flow-Set Fluorospheres™ (Beckman Coulter™; PN 6607007)
3) CYTO-COMP Reagent 1 (HCT/RDl) (Beckman Coulter™; PN 6607021)
4) CYTO-COMP Reagent 2 (RDl/ECD)
5) CYTO-COMP Reagent 3 (RD1/PC5)
6) CYTO-COMP Reagent 4 (ECD/PC5)
7) CYTO-COMP™ Cells (Beckman Coulter™; PN 6607023)
8) IMMUNO-TROL™ whole control blood (Beckman Coulter™; PN 4238091-E)
9) CYTO-STAT® tetraCHROME™ Reagent CD45-FITC/CD4-RD1/CD8-ECD/CD3-PC5 
Monoclonal Antibody Reagent (Beckman Coulter™ ; PN 6607013)
10) CYTO-STAT® tetraCHROME™ Reagent CD45-FITC/CD56-RD1/CD19-ECD/CD3- 
PC5 Monoclonal Antibody Reagent (Beckman Coulter™; PN 6607073)
11) lOTest® Conjugated CD16-PE (ImmunoTech™; PN IM1238)
12) OptiLyse C ® (Beckman Coulter™; PN IM1401)
13) Phosphate Buffered Saline (PBS)
^Dissolve one PBS package into 1 L of deionized water.
>Adjust pH to 7.2.
Stability and Storage o f Solutions:
>Store antibodies, calibration and compensation reagents ( 1-11) in refiigerator at 
2-8 “C.
>Store OptiLyse (12) and PBS (13) at room temperature.
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Appendix E - Reagents for Glutamine Analysis
1) Acetate Buffer (0.5 mol/1, pH 5.0):
a) >  Dissolve 6.8 g C^HsOjNa • 3 H2O (Sodium Acetate Trihydrate) in deionized 
water and make up to 100 ml.
b) >• Dilute 2.9 ml glacial acetic acid to 100 ml with deionized water.
>  Mix 67.8 ml (la) with 32.3 ml (lb).
2) L-glutamine standard solution (2 mmol/1):
a) >  Dissolve 292 mg L-glutamine in 10 ml deionized water.
b) >  Dilute 0.1 ml solution (a) to 10 ml with deionized water.
3) Glutaminase (10 kU/1):
>  Dissolve 10 U glutaminase powder (60m E. coli, lyophilized powder, 20-30 U 
per mg protein at 37°C; essentially free &om glutamate decarboxylase; 
commercial preparation Grade V from Sigma) in 1 ml acetate buffer (use 0.1 ml 
solution ( 1 ) flu ted  with 0.9 ml deionized water).
4) Tris/Hydrazine Buffer [0.1 mol/1 Tris (2-amino-2-(hydro)qrmethyl)-l,3-propanediol); 2 
nunol/1 H3TA; 0.63 mol/1 hydrazine]:
^Dissolve 1.2 g Tris and 74 mg EDTA-NajHj • 2 HjO in approximately 60 ml 
deionized water.
>A dd 5 ml hydrazine hydrate (62%, w/v).
> Adjust to pH 9 with 5 mol/1 HCL, and make up to 100ml with deionized water.
5) Nicotinamide-adenine Dinucleotide (P-NAD, 30 nunol/1):
^Dissolve 200 mg NAD, fiee acid, in 10 ml deionized water.
6) Adenosine 5'-diphospate (ADP, lOOmmol/1):
^D issolve 42.7 mg ADP, free acid, in water, neutralize with 0.1 ml 2mol/l NaOH 
and make up to 1 ml with deionized water
7) Glutamate Dehydrogenase (GIDH, 1200 kU/1)
>U se stock solution fit>m beef liver, 10 mg/ml in glycerol, 120 U/mg at 25 °C
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8) Perchloric Acid (10 % v/v):
>D ilute 10 ml perchloric acid (60 %, w/w, sp. gr. 1.54) to 60 ml with deionized 
water.
9) Potassium Hydroxide (KOH, 20 % w/v):
^Dissolve 20 g KOH in 100 ml deionized water
Stabilitv and Storage of Solutions:
>Store buffer solutions (I), and (4) in refrigerator (2-8®C).
>The Tris/hydrazine buffer (4) is stable for 7 days.
>Store solutions (2), (3), (5), and (6) in deep frwze (-20 °C). Make working 
aliquots.
>T he Glutamate Dehydrogenase is stable for at least 12 months at 4°C.
Calçalatiçin?
>C1 = sum of glutamine concentrations after deamination of endogenous 
glutamate.
>C 2 = sum of glutamate concentration.
>C 3 = sum o f glutamine concentration.
> V  = volume of sample in ml.
> D  = dilution factor
Aabsorbance in C2 - Aabsorbance inC l =C3 ^  V xD
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Appendix F - Reagents for Saliva IgA Analysis
1) Anti-human IgA (a-chain specific) developed in Rabbit
2) Purified Human Colostrum IgA 2S00mg/L.
3) Anti-human IgA (a-chain specific) Peroxidase Conjugate F(ab')z developed in goat
4) Coating buffer
^Dissolve 0.8g NagCO) (Sodium Carbonate)
^D issolve 1 45g NaHCO, (Sodium Bicarbonate)
>Adjust pH to 9.6. Make up to final volume o f SOO ml with deionized water.
5) Washing Buffer
>Dissolve 16 g NaCl (Sodium Chloride)
^Dissolve 0.4 g KCl (Potassium Chloride)
>Dissolve 0.4 g KH^PO  ̂(Monopotassium Phosphate)
^D issolve 5.8 g NazHPO  ̂(Monosodium Phosphate)
^D issolve 2 g Tween-80
>Adjust to pH 12. Make up to final value o f 2L with deionized water.
6) Phosphate Buffered Saline (PBS):
^D issolve 1 PBS package into IL  of deionized water.
>>Adjust pH to 7.2
7) Blocking Protein (2% w/v):
^D issolve 0.8g o f Bovine Serum Albinnin in 40 ml PBS.
8) OPD (o-Phenylenediamine Dihydrochloride) Peroxidase Conjugate Substrate:
^D issolve one OPD tablet and one urea hydrogen peroxide/buffer tablet into 20 
deionized water.
^Protect from light by wrapping in foil.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Glutamine and the Inunune System 94
Stability and Storage o f Solutions:
>Store reagents (1-3) in deep freeze (-20 °C) in working aliquots. 
>Coating Buffer (4) is stable in refrigerator (2-8 °C) for 14 days.
>PBS (6) and Washing Buffer (S) are stable at room temperature. 
^Prepare Blocking Protein (7) and Substrate (8) before each procedure.
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Appendix G - Subject Instructions
Supplementation Instructions
1) Please do not compare treatments (supplement) with other participants in the stwfy.
2) Please start supplementation TODAY. Remove a three dose package each day. Take 
one bag o f supplement on three separate occasions (4-8 hrs apart) for each of the next 14 
days (November 17* - November 30*).
3) Empty all the contents o f one bag into a flavoured drink of your choice, stir the contents 
and drink immediately. PLEASE NOTE: There are staples at the top of each three hag 
package. Please take care to ensure that a staple does not fall into your drink.
Nutritional Intake li
1) Record your dietary intake for October 16* I7*&  18* and for November 30*, 
December 1“ & 2“*.
2) Please be as specific as possible. Your description should include the type of food as 
well as the quantity. For example - if you ate a tuna sandwich with a glass of milk for 
lunch your description could be something like this — 2 slices of white bread, 2 teaspoons 
of light mayo, 100 grams of tuna (in water), 2 cups (500ml) o f 1% milk.
Training Log Instructions 
1 ) Please start a training log TODAY.
2) Outline the type o f training (running, w ei^ ts etc.), volume (reps/sets, mileage), 
duration, and intensity (% o f max) for each o f the next 14 days (November 17* - 
November 30*).
3) Please bring a copy o f your training log with you on the next test session.
Next Test Session
Your next test session will be December 1" at
If you have any questions about these procedures please contact Joe by phone at 346-7815 
(office), 577-9541 (home) or e-mail atjquadril@tnail.lakeheadu.ca.
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Appendix H - Social Readjustment Rating Scale
Rank LHe Event Value
1 Death of spouse 100
2 Divorce 73
3 Marital separstioo 65
4 Jail term 63
5 Deadi of a close finnity member 63
6 Personal mjmy or flhiess 55
7 Marriage 50 .
8 Fired at work 47
9 Marital leoonciliatioa 45
10 Rethemeot 45
11 Change m healdi of a ftmify member 44
12 Pregnancy 40
13 Sex difiBadties 39
14 Gam of a new Amily member 39
15 Business teadjnsonent 39
16 Change in financial state 38
17 Deadi of a close fiund 37
18 Change to difkrent line at work 36
19 Change in the number of arguments with spouse 35
20 Mortgage over 810,000 3J
21 Foreclosure of mortgage or loan 30
22 Change in responsibilities at work 29
23 Son or dau^iter leaving home 29
24 Trouble widi in-laws 29
25 Outstanding personal adnevement 28
26 Spouse begins or stops work 26
27 Begin or end of school 26
28 Change in living condhioos ' 25
29 Revision of personal habits 24
30 Trouble widi boss 23
31 Changent work hours or conditioos 20
32 Change m residence 20
33 Change in school 20
34 Changem recreatian 19
35 Change in churdLuctivities 19
36 Change m sodal activities 18
37 Mortgage or loan less than $10,000 17
38 Change in slequng habits 16
39 Change m iiiuriber of finnibf get4ogethen 13
40 Change in eatinghalnts 15
41 Vacation 13
42 Christmas 12
43 AÆnorviolatioo of die law 11
Holmes and Rahe, 1967
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Appendix I - Social Validation Questionnaire
1 ) Did you observe any differences in the two different supplements that you received? If 
so explain.
2) Do you have any idea which supplement was the glutamine and which was the 
placebo?
Yes_________  or N o__________ If yes, please answer below.
Supplement Period #1___________________________
Supplement Period #2___________________________
3) Did the first or second supplements give you any problem? If so explain.
4) Did you feel any positive effects from either o f the supplements (ie. Increased 
performance, increased health status etc.)?
S) Would you participate in a stwfy of this nature again? Please explain.
6) Would you change anything about this study? Explain
N a m e _______________________Date
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Glutamine and the Immune System 98
Appendix J  - ANOVA Source Tables
2W ayANOVATABLE 
Leukocyte Count
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.0024 14 0.07859 0.03 0.86
Treatment
(Glutamine vs Placebo)
1 0.08513 14 0.206 0.41 0.53
Time x Treatment 1 1.33206 14 0.367 3.63 0.08
2 Way ANOVA TABLE 
Neutrophil Count
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.0034 14 0.0631 0.05 0.82
Treatment
(Glutamine vs Placebo)
1 0.4455 14 0.08672 5.14 0.04
Time x Treatment I 1.1016 14 0.2906 3.79 0.07
2 W ay ANOVA TABLE 
Basophil Count
Source dfEffect MS Effect df Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0 14 0 O.I 0.75
Treatment
(Glutamine vs Placebo)
1 0.001 14 0 0.45 0.51
Tim ex Treatment I 0 14 0 0.01 0.93
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2 Way ANOVA TABLE 
Eosinophil Count
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.0028 14 0.0061 0.45 0.51
Treatment
(Glutamine vs Placebo)
1 0.07884 14 0.11706 0.67 0.43
Time x Treatment 1 0.0016 14 0.001 1.76 0.21
2 Way ANOVA TABLE 
Monocyte Count
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.0066 14 0.0043 1.52 0.24
Treatment
(Glutamine vs Placebo)
1 0.001 14 0.0048 0.21 0.66
Time x Treatment 1 0.0023 14 0.0033 0.7 0.42
2 Way ANOVA TABLE 
Lymphocyte Count
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.0016 14 0.03139 0.05 0.82
Treatment
(Glutamine vs Placebo)
1 0.01485 14 0.03832 0.39 0.54
Time x Treatment 1 0.001 14 0.02105 0.28 0.87
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2 Way ANOVA TABLE 
T lymphocyte Count
Source dfEffect MS Effect df Error MS Error F-Ratio p level
Time (Pre vs Post) I 0 14 0.01854 0.02 0.9
Treatment
(Glutamine vs Placebo)
1 0.01493 14 0.02289 0.65 0.43
Time x Treatment 1 0 14 0.01359 0.01 0.95
2 Way ANOVA TABLE 
Helper T Lymphocyte Count
Source dfEffect MS Effect df Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0 14 0.0085 0.05 0.83
Treatment
(Glutamine vs Placebo)
1 0.0048 14 0.01115 0.43 0.52
Time x Treatment 1 0.0011 14 0.006 0.18 0.68
2 Way ANOVA TABLE 
Cytolytic T lymphocyte Count
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0 14 0.0019 0.06 0.81
Treatment
(Glutamine vs Placebo)
1 0.0034 14 0.0023 1.45 0.25
Time x Treatment 1 0.001 14 0.0013 0.43 0.52
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2 Way ANOVA TABLE 
B lymphocyte Count
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0 14 0.001 0.68 0.42
Treatment
(Glutamine vs Placebo)
1 0.0013 14 0.0013 1.02 0.33
Time x Treatment 1 0.001 14 0 2.07 0.17
2 Way ANOVA TABLE 
Natural Killer Cell Count
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.0038 14 0.002 1.92 0.19
Treatment
(Glutamine vs Placebo)
1 0 14 0.0046 0.01 0.91
Time x Treatment I 0.001 14 0.002 0.27 0.61
2 Way ANOVA TABLE 
Percent Neutrophils
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.1042 14 8.886 0.01 0.92
Treatment
(Glutamine vs Placebo)
1 82J68 14 15.452 5.33 0.04
Time x Treatment 1 61 14 27.271 2.87 0.11
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2 Way ANOVA TABLE 
Percent Basophils
Source dfEffect MS Effect df Error MS Error F-Ratio p level
Time (Pre vs Post) I 0.0016 14 0.05301 0.03 0.87
Treatment
(Glutamine vs Placebo)
1 0.0525 14 0.03741 1.4 0.26
Time x Treatment I 0.0758 14 0.06418 1.18 0.3
2 Way ANOVA TABLE 
Percent Eosinophils
Source dfEffect MS Effect df Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.5487 14 1.58144 0.35 0.57
Treatment
(Glutamine vs Placebo)
1 18.98 14 23.7195 0.8 0.39
Time x Treatment 1 0.0059 14 0.31811 0.18 0.89
2 Way ANOVA TABLE
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 1J2123 14 1.4337 0.85 0.37
Treatment
(Glutamine vs Placebo)
1 0.08067 14 1.2521 0.06 0.8
Time x Treatment 1 1.4415 14 1.46666 0.98 0.34
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2 Way ANOVA TABLE 
Percent Lymphocytes
Source dfEffect MS Effect df Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.486 14 9.675 0.05 0.83
Treatment
(Glutamine vs Placebo)
1 23.064 14 17.729 1.3 0.27
Time x Treatment 1 38.4 14 18.555 2.07 0.17
2 Way ANOVA TABLE 
Percent T lymphocytes
Source dfEffect MS Effect df Error MS Error F-Ratio p level
Time (Pre vs Post) 1 1.70017 14 2.9803 0.57 0.46
Treatment
(Glutamine vs Placebo)
1 3.40817 14 7.09585 0.48 0.5
Time x Treatment I 0.10417 14 3.65577 0.03 0.87
2 Way ANOVA TABLE 
Percent CD3+CD4+ lymphocytes
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.4167 14 4.4495 0.09 0.76
Treatment
(Glutamine vs Placebo)
1 1.23267 14 5.6741 0.22 0.65
Time x Treatment 1 2.3207 14 3.1749 0.73 0.41
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2 Way ANOVA TABLE 
Percent CD3+CM+ lymphocytes
Source dfEffect MS Effect df Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.02817 14 0.341 0.08 0.78
Treatment
(Glutamine vs Placebo)
1 2.94817 14 0.7267 4.06 0.06
Time x Treatment 1 1.38017 14 1.298 1.06 0.32
2 Way ANOVA TABLE 
CD4/CD8 Ratio
Source dfEffect MS Effect df Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.001 14 0.01121 0.08 0.78
Treatment
(Glutamine vs Placebo)
1 0.01457 14 0.01685 0.87 0.37
Time x Treatment 1 0.03558 14 0.01949 1.83 0.2
2 Way ANOVA TABLE 
Percent CD19 lymphocytes
Source dfEffect MS Effect df Error MS Error F-Ratio p level
Time (Pre vs Post) 1 0.15 14 0.423 0.35 0.56
Treatment
(Glutamine vs Placebo)
1 0.726 14 1.1421 0.64 0.44
Time x Treatment 1 0.384 14 1.0994 0.35 0.56
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2 Way ANOVA TABLE 
Percent CD3-CD16+CD56+ lymphocytes
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 3.80017 14 5.22588 0.73 0.41
Treatment
(Glutamine vs Placebo)
1 0.40017 14 12.5373 0.03 0.86
Time x Treatment 1 0.20417 14 5.5556 0.04 0.85
2 Way ANOVA TABLE 
Saliva IgA
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 2475.41 14 2770.23 0.89 0.36
Treatment
(Glutamine vs Placebo)
I 2211.85 14 2449.43 0.9 0.36
Time x Treatment 1 1244.6 14 2385.63 0.52 0.48
2 Way ANOVA TABLE 
Plasma Glutamine
Source dfEffect MS Effect d f Error MS Error F-Ratio p level
Time (Pre vs Post) 1 2642.72 14 11139.99 0.24 0.63
Treatment
(Glutamine vs Placebo)
1 23784.49 14 12108.47 1.96 0.18
Time x Treatment 1 462.15 14 9663.31 0.05 0.83
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3 Way ANOVA TABLE 
Leuko^te Count by Gender
Source dfEffect MS Effect d f Error MS Error F-R atio p level
Gender (Male vs 
Female)
I 0.31447 13 5.5314 0.06 0.82
Time
(Pre vs Post)
1 0.0031 13 0.0845 0.04 0.85
Treatment
(Glutamine vs Placebo)
1 0.02601 13 0.19169 0.14 0.72
Gender x Time 1 0.0015 13 0.0845 0.18 0.9
Gender x Treatment 1 0.38809 13 0.19169 2.03 0.18
Time x Treatment 1 1.90678 13 0.27472 6.94 0.02
Gender x Time x 
Treatment
1 1.56288 13 0.27472 5.69 0.03
3 Way ANOVA TABLE 
Neutrophil Count by Gender
Source dfEffect MS Effect d f Error MS Error F-R atio p level
Gender (Male vs 
Female)
1 0.03969 13 2.00218 0.02 0.89
Time
(Pre vs Post)
1 0.0014 13 0.0672 0.02 0.89
Treatment
(Glutamine vs Placebo)
1 0.35469 13 0.0868 4.09 0.06
Gender X Time 1 0.01003 13 0.67217 0.15 0.71
Gender x Treatment 1 0.08525 13 0.0868 0.98 0.34
Time x Treatment 1 1.67281 13 0.17789 9.4 0.01
Gender x Time x 
Treatment
1 1.75561 13 0.17789 9.87 0.01
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3 Way ANOVA TABLE 
Percent Neutrophib by Gender
Source dfEffect MS Effect d f Error MS Error F-R atio p level
Gender (Male vs 
Female)
I 49.6547 13 177.339 0.28 0.61
Time
(Pre vs Post)
1 0.0562 13 8.9802 0.01 0.94
Treatment
(Glutamine vs Placebo)
1 75.1674 13 16.546 4.54 0.05
Gender X Time I 7.6563 13 8.9802 0.85 0.37
Gender x Treatment 1 1.2367 13 16.546 0.08 0.79
Time x Treatment I 107.693 13 8.6293 12.48 0
Gender X Tim ex 
Treatment
1 185.617 13 8.6293 21.51 0
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